

PRESIDENT'S COLUMN

Curtis E. Haas, Pharm.D., FCCP, BCPS



It is another busy year for ACCP as we as an organization pursue our objectives addressing the three critical issues defined in our strategic plan—to develop, advance, and position clinical pharmacists in practice, research, and education. In my opinion, the PRNs remain the lifeblood of the organization, serving as the vehicles that permit and encourage our members to remain connected and interactive throughout the year. The PRNs represent the single greatest member benefit for many ACCP members. I would like to share many important issues with the PRNs in this column to hopefully generate both awareness and discussion among the many members who interact regularly with their PRN colleagues, but space limits restrict me to the three topics below.

Medicare Coverage Initiative for Direct Patient Care Services of Qualified Clinical Pharmacists

This is the “official” title for the ACCP pharmacist—“provider initiative.” The two-page document at www.accp.com/MedicareBrief should be considered required reading for all ACCP members—it will require only a few minutes of your time.... This document summarizes in clear, brief language the purpose, background, and rationale—the “what” and the “who” of this initiative. The title is very important because it emphasizes that this is about benefits provided to a patient by qualified clinical pharmacists (i.e., it is focused on improving patient care and outcomes, not on creating opportunities for pharmacists). It also embraces the reality that the Social Security Act (42 U.S.C. and relevant sections, primarily section 1861) defines the coverage of health care services, not “provider status”; nor does it offer a list of recognized providers. This is the single largest and most important legislative and advocacy agenda item for ACCP, and this initiative will need the awareness and support of every

member as we move forward on it. The staff leadership is currently engaged in active outreach and advocacy within and outside the profession to generate support, identify partners, and engage them in this initiative. At the right time, grassroots advocacy by our members will also be an important need—so stay tuned!

A related and very important commentary endorsed by the Board of Regents (BOR) has also been released this month and should be another important piece of recommended reading ... requiring another 5- to 10-minute investment of your time. The paper, titled “Qualifications of Pharmacists Who Provide Direct Patient Care: Perspectives on the Need for Residency Training and Board Certification,” is available as a prepublication draft at www.accp.com/docs/positions/commentaries/ACCP_Brd_Commnrty_Final_030513.pdf. My column in the March ACCP Report (www.accp.com/report/index.aspx?iss=0313&art=7) provides some more detailed thoughts on this paper and its central importance to the Medicare coverage initiative.

Most members will agree that this is a very important initiative and realize that it will take a great deal of work, effective strategy, and probably a bit of good luck to be successful. I encourage every PRN member to seriously consider contributing to the ACCP Political Action Committee—there has never been a more important time for us to generate resources to support the legislative agenda. To save you time (to read the papers recommended earlier!), here is the link that will take you directly to the ACCP-PAC site, where it is very easy to make a donation: www.accpaction.org/signin/index.aspx. Thank you in advance for considering a generous contribution.

Board Certification Update

Through concerted action with our partner sponsoring organizations, the well-stated ACCP objective of increasing opportunities for board certification is continuing to move forward. The Board of Pharmacy Specialists has just

announced the approval of critical care pharmacy and pediatric pharmacy as specialties. See the article on page 3 for more information on the BPS announcement.

In addition, BPS has established Practice Analysis Task Forces for cardiology and infectious diseases in response to preliminary requests for specialty recognition submitted by ACCP and partner organizations. The task forces were created as part of the process for conducting role delineation studies for the proposed specialties. We stand prepared to serve as a sponsoring organization for these specialties once a call for petitions is issued pursuant to an analysis of the role delineation studies by BPS.

BPS has also announced the movement to computer-based testing, with an expansion of both testing dates and testing locations to increase access to board certification examinations.

Another important development under the heading of board certification is the publication of a white paper by BPS that defines its 5-year vision for pharmacy specialties (www.bpsweb.org/pdfs/BPS_Whitepaper_Jan2013.pdf). This vision is in some ways aligned with the ACCP Medicare coverage initiative and qualifications of clinical pharmacists commentary referenced earlier. In fact, the vision paper states that there will be “a future model where board certification will be the expectation for pharmacists engaged in direct patient care.” The vision also commits to the continued expansion of specialty recognition that is consistent with, but not limited to, the growth of PGY2 residency training programs, and that BPS will be considering modifications to the specialty recognition structure. These statements are not inconsistent with a white paper published by ACCP in 2009 evaluating the need to consider a restructuring of the specialty framework (www.accp.com/docs/positions/whitePapers/Pharm2902_ACCP-Blair-Specialists.pdf). This white paper from the BPS Board represents potentially positive developments for ACCP and its members who are heavily invested in the importance of BPS board certification.

Student Chapters

The last topic I wanted to touch on is the development toward the recognition and establishment of ACCP student chapters on the campuses of our schools and colleges. Students have been the fastest-growing membership category for the past several years, and they represent the future of the College. I believe this is a clear indication that more and more student pharmacists recognize that the future of the profession will be progressively dependent on the growth of clinical pharmacy and direct patient care, and they realize that ACCP is the professional home most aligned with that recognition.

Our student members have also been very vocal about the importance to them of student chapters in order to have an organized local presence. In November, the Board of Regents authorized the establishment of student chapters and requested that staff begin the process of defining the policies and processes that will be necessary to make this a reality. The ACCP staff have been very busy working on that charge and, later this year, will announce the process and requirements for establishing student chapters. The PRNs have always been strong advocates for, and staunch supporters of, our student members and have served as a great introductory pathway for students to realize the value of ACCP membership and to serve the organization. I am certain the PRNs are going to fully embrace the increased presence and roles of our students in the organization, and with time, there may be some interesting ways for the PRNs to interact with student chapters. The creation and growth of student chapters will represent another important milestone in the sustained growth and success of ACCP as an organization dedicated to the development, advancement, and positioning of clinical pharmacists.



PRNS PREPARE FOR ELECTIONS

The PRN election cycle is upon us. It is time for the PRNs to begin the process of determining who will serve as officers in the coming year. If you are interested in being a PRN officer or in nominating someone, please contact your PRN's chair.

Election Process

The Nominations Committee will consist of at least two individuals appointed by the PRN's chair. These individuals may be the PRN's current elected officers. Those who are on a PRN's nominations committee will be ineligible to run for office in that PRN's election that year.

The Nominations Committee should prepare a slate of candidates and shall provide information to each candidate related to the election procedures. The Nominations Committee shall also provide a time line and a list of expected duties. When possible, two or three candidates for each office shall be up for election. If only one candidate can be identified, an election will still be held, with voters given the option of identifying a write-in candidate. When there are more than three possible candidates, the PRN's Nominations Committee will be responsible for narrowing the slate to three candidates. The Nominations Committee will obtain a brief (250 words) biographical sketch or candidate statement from each the candidate.

Voting

As in previous years, PRN elections will be held online. PRN members will receive an e-mail from ACCP that outlines the voting procedure. Members will use their log-in and password to access the ACCP Web site. Each member will then be able to access the ballot for each PRN of which he or she is a current member. Members should review their e-mail and the ACCP Web site for further news about online voting as the election draws closer.

2013 Election Timetable

PRN call for nominations	March 2013
Submission of slates and candidates to ACCP	June 14, 2013
Electronic balloting opens	July 12, 2013
Electronic balloting closes	August 19, 2013 (6–8 weeks before the Annual Meeting)
Committee contact notified of results	August 26, 2013
Nominations Committee notifies all candidates of election results	August 28, 2013 (within 10 days of election)
ACCP staff notify new officers of meeting date and time at the Annual Meeting	September 2013



PRN NETWORKING BREAKFASTS RETURN TO RENO, NEVADA

ACCP's PRNs provide a focal point for clinical pharmacists with common interests and needs in practice, research, and education. PRN members help ACCP develop educational programs and promote the activities of the PRNs. Now in their third year, the popular ACCP PRN networking breakfasts will continue at the 2013 Updates in Therapeutics® in Reno, Nevada.

Join ACCP and your fellow meeting attendees for a complimentary continental breakfast each day, Saturday through Monday, from 7:30 a.m. to 9:00 a.m. (PDT) in the Tuscan ballrooms of the Peppermill Resort. Many PRNs will have a designated table where attendees can meet PRN representatives and learn how to become involved. A listing of the PRNs who will be hosting tables during each breakfast session follows.

Saturday, April 20: 7:30 – 9:00 a.m.

Ambulatory Care PRN
Cardiology PRN

Emergency Medicine PRN
Immunology/Transplantation PRN
Pediatrics PRN
Women's Health PRN

Sunday, April 21: 7:30 – 9:00 a.m.

Adult Medicine PRN
Ambulatory Care PRN
Cardiology PRN
Education and Training PRN
Geriatrics PRN

Monday, April 22: 7:30– 9:00 a.m.

Ambulatory Care PRN
Cardiology PRN
Drug Information PRN



SAVE THE DATE FOR THE 2013 ACCP VIRTUAL POSTER SYMPOSIUM

Mark your calendar for the first ACCP Virtual Poster Symposium to be held May 21–22, 2013. Posters will be on display May 21–22 for asynchronous viewing and comment. In addition, two interactive sessions will be scheduled from 7:00 p.m. to 9:00 p.m. (EDT) on May 21 and 22.

During both of the interactive sessions, authors will be available for real-time online question-and-answer sessions alongside their virtual posters. The technology required for attendees is minimal—a broadband Internet connection, a current browser, and Skype (free software). Posters will be presented in the Original Research, Clinical Pharmacy Forum, and Student and Resident Research-in-Progress categories, with about 60–70 posters presented each evening.

Take advantage of this opportunity to network with your colleagues and learn more about what ACCP members and nonmembers are doing in their practice sites—all from the comfort of your home or office. No travel is required. Registration for this symposium is free to all ACCP members and is available at www.accp.com/myaccount.

BPS APPROVES PETITIONS RECOGNIZING PEDIATRICS AND CRITICAL CARE AS NEW SPECIALTIES

The Board of Pharmacy Specialties (BPS) Board of Directors has approved petitions to recognize the areas of pediatric pharmacy practice and critical care pharmacy practice as specialties in pharmacy. The BPS announcement is available at http://www.bpsweb.org/news/pr_041513.cfm.

ACCP, working collaboratively with the American Pharmacists Association (APhA), the American Society of Health-System Pharmacists (ASHP), and the Pediatric Pharmacy Advocacy Group (PPAG), developed the petition to recognize pediatric pharmacy practice. For the critical care petition, ACCP partnered with APhA and ASHP. In both cases, the petitions were developed by a working group consisting of a practitioner-clinician member in the specialized area of practice and a member of the professional staff from each organization. Both petitions were submitted to BPS in November 2012.

BPS will now begin the process of forming a specialty council for each new specialty, which will be charged with developing the certification examination, proposing eligibility criteria for pharmacists to take the examination, and managing other required details for BPS to consider in implementing the certification processes. Examinations in both specialties will be available as early as 2015. Further information about the time line and process can be found during the next few weeks on the BPS Web site (www.bpsweb.org).

TEST YOURSELF ON ACCP'S RECERTIFICATION PROGRAMS AND THEN CHECK THE DASHBOARD

As an ACCP member, you're the first to hear about new programs available from ACCP for specialty recertification. But how much do you really know about new and improved products for recertification in pharmacotherapy and ambulatory care pharmacy? Take the following quiz to find out, and then read on for news about the ACCP Recertification Dashboard: a new recertification planner to help you stay on track as you work toward recertification.

Test Yourself

1. True or false: A Board Certified Pharmacotherapy Specialist can no longer recertify using PSAP alone.

Answer: False. The new six-book PSAP series offers 40 hours per year of continuing pharmacy education credit approved by BPS for BCPS recertification. That's 120 available hours from 2013 through 2015, plus another 120 hours from 2016 through 2018. All together, PSAP will offer 280 hours of recertification credit over a 7-year recertification cycle.

In addition, you will now have 4 months to complete and submit each PSAP module—a full month longer than in previous editions.

2. True or false: Board Certified Ambulatory Care Pharmacists can use PSAP to recertify in ambulatory care pharmacy.

Answer: False. ACCP has just introduced a new home study series developed specifically for recertification in ambulatory care pharmacy: the *Ambulatory Care Self-Assessment Program (ACSAP)*. The six scheduled releases in the ACSAP series are electronic books (PDFs) with enhanced interactivity. Intra-document links lead you from the table of contents to specific chapter topics; authority links take you to current guidelines, online tools, or agency resources; and hundreds of reference links connect you to PubMed, the Cochrane Database, and other compilers so that you can access the original sources of this information.

ACSAP is available in an e-media package that allows access on phones, tablets, and e-readers. ACSAP will offer a minimum of 20 hours of BCACP recertification credit annually through the release of two electronic books—the first in January, followed by a second in July. Full details on the ACSAP series are available at www.accp.com/bookstore/acsap.aspx.

3. True or false: The pharmacotherapy prep course can be used for recertification.

Answer: True. Board Certified Pharmacotherapy Specialists may use the Pharmacotherapy Preparatory Review and Recertification Course up to two times during a 7-year recertification cycle, in nonconsecutive years. The course is available live and in a variety of home study formats. It will provide a minimum of 21 hours of BPS-approved recertification credit annually. This means that a pharmacotherapy specialist could earn at least 42 hours of recertification credit by participating in the review and recertification course twice during his or her 7-year recertification cycle—if the courses are taken in nonconsecutive years.

4. True or false: All the recertification offerings for ambulatory care are released in the spring and summer. If you miss them, you'll have to wait until next year.

Answer: False. BCACPs can attend the live presentation of From Theory to Practice: Clinical Reasoning Series in Ambulatory Care Pharmacy, offered as a presymposium at ACCP's Annual Meeting each October. With new content each year, the live program allows BCACPs to earn a minimum of 6 hours of BPS-approved recertification credit in ambulatory care pharmacy every year.

5. True or false: PSAP won't work on portable electronic devices.

Answer: False. When you purchase the PSAP E-Media Package, you'll receive the basic version of the product: online printable PDFs that include full text, full-color graphics, and self-assessment questions; hyperlinks to outside resources such as official guidelines; reference links to compilers such as PubMed; and multimedia elements (audio and video). You'll also receive the full text (without graphics) and self-assessment questions for e-reader devices—phones and tablets. In addition, you will receive both the graphics as separate image files and the PSAP audio companion.

Full information about the PSAP E-Media Package is available at www.accp.com/bookstore/psap.aspx#new.

Here's a final bonus question to test your knowledge of BPS recertification requirements generally.

True or false: To make sure you've earned enough credits to recertify using continuing pharmacy education, it's best to complete as many hours as possible early in your recertification cycle.

Answer: False. In the early years of the recertification cycle, BPS limits the number of hours that can be counted toward recertification, although all the required hours may be earned later in the cycle. For pharmacotherapy specialists, that means that no more than 60 hours may be earned before the end of the fourth year of the cycle. For specialists in ambulatory care pharmacy, no more than 50 hours may be earned before the end of the third year of the cycle.

NEW ACCP RECERTIFICATION DASHBOARD TO HELP RECERTIFICANTS STAY ON TRACK

If you're feeling a bit overwhelmed with information about available offerings for recertification, and keeping track of your hours earned, help is on the way: the ACCP Recertification Dashboard. ACCP has just released the new online recertification planner to help members who are board certified in oncology, pharmacotherapy, or ambulatory care—the specialties in which ACCP is the provider or co-provider of recertification offerings. The free online planner is designed to help you keep track of hours earned and upcoming offerings available to you, all within the requirements set up by BPS, so that you're better organized and better prepared for each recertification cycle.

For full information on the ACCP Recertification Dashboard, read the article in the April issue of the *ACCP Report*. Or check the dashboard directly at www.accp.com/myaccount/recertdashboard.aspx.

GUIDANCE ON PRN E-MAIL LIST DISCUSSIONS

The PRN e-mail lists are intended to facilitate and stimulate meaningful and appropriate discussion among PRN members concerning professional issues in patient care and appropriate drug therapy. Discussions concerning challenging clinical questions or therapeutic approaches are not only appropriate but are also welcomed. Clearly, these are benefits to each PRN member and are encouraged.

However, it is imperative that the PRN e-mail service not be used in a way that might be perceived by an outside agency as contributing to any illegal or unethical conversations. For example, discussions, questions, or answers concerning the establishment of specific prices, charges, costs, or values for products or services could be perceived as price collusion between competing clinicians or institutions. Recommendations favoring or disfavoring a particular vendor, service provider, or product could be viewed as an illegal boycott. Even if the answers sought appear to be couched in a seemingly harmless survey, it should be understood that these types of inquiries could result in time-consuming, expensive, and detrimental investigations by an outside agency/authority. For these reasons, ACCP strongly encourages all PRN members to avoid these types of questions or surveys so that the integrity of ACCP and the PRNs does not come into question.

Following are suggestions for the effective use of the PRN e-mail lists to facilitate communication among PRN members.

E-mail List Etiquette and Procedures

1. Include a signature on all messages. The signature should include your name, affiliation, location, and e-mail address.
2. Clearly articulate in your communication whether the information being provided represents factual information/data or is a professional or personal opinion.
3. Recognize, and be sensitive to the fact, that use of the e-mail list is a "public" activity subject to the subpoena power of law enforcement authorities, like most other forms of communication. There should be no expectation of privacy in e-mail list communications.
4. It is recommended that you send all of your messages to an e-mail list in plain text format as opposed to rich text or HTML.
5. When you receive a message directed to the list, selecting the Reply button in your e-mail program

will send the response to the author of the message. Selecting the Reply All button in your e-mail program will send your response to the original author as well as the entire list. Always double-check the name or address you are replying to when responding to a message transmitted by an e-mail list.

6. If you receive an unwanted message from a list member who does not observe these rules, please do not respond to the list. Instead, ignore the message or, if you feel the need to respond to the sender, make certain you reply only to the sender.
7. If you plan to use an automatic e-mail response to indicate that you are out of the office, please remember to set your subscription type to NOMAIL until you return.

Prohibited Communications

The following types of communications must be strictly avoided on all PRN e-mail lists because of their actual or perceived violation of federal laws related to restraint of trade and/or anti-competitive practices:

1. Comments, recommendations, questions, or answers concerning the establishment or amounts of specific prices, charges, or costs for products and/or services, sharing of fee structures, or financial information that could suggest possible price collusion between competitors (e.g., competing clinicians or institutions).
2. Recommendations that favor or disfavor a particular vendor or service provider based on the price of those services (e.g., directly or indirectly recommending a “boycott” of a product or service based on price).
3. Opinions that stray toward or may suggest prohibited activities cited above.



PRN NEWS BRIEFS

Adult Medicine PRN

The Adult Medicine PRN consists of practitioners, residents, and students who have an interest in shaping the practice of adult medicine in a variety of inpatient and outpatient settings. The PRN currently has around 1000 members with diverse research, practice, education, and training experiences. The following paragraphs highlight some of the Adult Medicine PRN’s activities and member accomplishments.

Looking toward the ACCP Annual Meeting next fall, the Adult Medicine PRN has been actively planning two focus sessions. Tentatively, the first session will focus

on all things statin, and the second is a joint session with the GI/Liver/Nutrition PRN that will focus on updates in the management of hepatic disease.

The PRN has been busy developing PRN-specific awards and detailing the award process. Several award recipients were recognized at the PRN’s business meeting last fall. Details can be found below.

Promotions

- Jessica Starr, Pharm.D., BCPS; associate clinical professor of pharmacy practice at Auburn University.

Awards

- Last fall at the Adult Medicine PRN business meeting, several of our members were recognized with PRN-specific awards: Mentoring Award – Julie Murphy, Pharm.D., BCPS; Resident Research Award – Kyle Sobecki, Pharm.D.; Student Research Award – Dante Gravino; Practitioner Registration Award – Mate Soric.
- Sharon See, Pharm.D., BCPS, was named to the Pharmacotherapy Specialty Council of the Board of Pharmacy Specialties.
- Sharon See, Pharm.D., BCPS, was recently selected as a 2013 Vincentian Research Fellow for St. John’s University.
- Sarah M. Gaffney, Pharm.D., BCPS, received the 2012 Virginia Society of Health-System Pharmacists (VSHP) Clinical Pharmacy Practice Achievement Award. This award is presented by VSHP to recognize one or more VSHP members who have made a recent contribution to the establishment and provision of a patient-oriented pharmacy service that produces visible outcomes.
- Jonathan Edwards and Mickala M. Thompson recently won the Silver Award at the Alabama Performance Excellence Awards Conference in January for their team showcase submission titled, “Impact and Advances of an Antimicrobial Management Team over Six Years.” The team consists of 15 participants from several disciplines. The team pharmacists include Edward H. Eiland III, Pharm.D., MBA, FASHP, BCPS (AQ-ID); Jonathan D. Edwards, Pharm.D., BCPS; Mickala M. Thompson, Pharm.D., BCPS; Nicholas L. Massie, Pharm.D.; and Michael McDaniel, BPharm, MBA, FASHP.

Grants

- Nancy Toedter Williams, Pharm.D., FASHP, BCPS, BCNSP, Southwestern Oklahoma State University (SWOSU), in partnership with Walgreens, was the recipient of a Community Pharmacy Residency Expansion Project grant for \$50,000.

Publications

- Soric MM, ed. Maximize Your Rotations: ASHP's Student Guide to IPPEs, APPEs, and Beyond. Bethesda, MD: American Society of Health-System Pharmacists, 2013.
- Wallace JL, George CM, Tolley EA, Winton JC, Fasanella D, Finch CK, Self TH. Peak expiratory flow in bed? A comparison of 3 positions. *Respir Care*. 2012 Aug 16. [Epub ahead of print]
- Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, Sands CW, Self TH. Comparison of initial warfarin response in obese patients versus non-obese patients. *J Thromb Thrombolysis*. 2012 Sep 27. [Epub ahead of print]
- Self TH, Wallace JL, Soberman JE. Cardioselective beta-blocker treatment of hypertension in patients with asthma: when do benefits outweigh risks? *J Asthma* 2012;49:947-51.
- See S, Ginzburg R. Gastroesophageal reflux disease. In: Richardson M, Chant C, Cheng JWM, Chessman KH, Hume AL, Hutchison LC, et al., eds. *Pharmacotherapy Self-Assessment Program*, 7th ed. Gastroenterology and Nutrition. Lenexa, KS: American College of Clinical Pharmacy, 2012:109-26.
- Sobieraj DM, White WB, Baker WL. Cardiovascular effects of pharmacologic therapies for smoking cessation. *J Am Soc Hypertens* 2013;7:61-7.
- Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM. Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet]. Rockville, MD: Agency for Healthcare Research and Quality, 2012.
- Bhardwaj S, Coleman CI, Sobieraj DM. Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis. *Am J Health Syst Pharm* 2012;69:1494-9.
- Sobieraj DM, White CM, Alikhanov S, Winkler S, Mediouni M, Kluger J, Coleman CI. The impact of antiplatelet and anticoagulant therapies on gastrointestinal symptoms in patients with atrial fibrillation: a systematic review. *Ann Pharmacother* 2012;46:1220-31.
- Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, Alam T. Dosing frequency and medication adherence in chronic disease. *J Manage Care Pharm* 2012;18:527-39.
- Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM. Comparative effectiveness of low-molecular weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis. *Pharmacotherapy* 2012;32:799-808.
- Coleman CI, Phung OJ, Cappelleri JC, Baker WL, Kluger J, White CM, Sobieraj DM. Use of mixed treatment comparisons in systematic review [Internet]. Rockville, MD: Agency for Healthcare Research and Quality, 2012.
- Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J, Kluger J, Makanji S, Ashaye AO, White CM. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. *Ann Intern Med* 2012;156:720-7.
- Vande Griend JP, Anderson SL. Histamine₁ receptor antagonism for the treatment of insomnia. *J Am Pharm Assoc* 2012;52:e210-9.
- Toussaint KA, Watson K, Marrs JC, Sturpe DA, Anderson SL, Haines ST. Prevalence of and factors that influence board certification among pharmacy practice faculty at United States colleges and schools of pharmacy. *Pharmacotherapy* 2013;33:105-11.
- Dolder CR, Olin JL, Alston G. Prospective measurement of a problem-based learning course sequence. *Am J Pharm Educ* 2012;76:Article 179.
- Olin JL, Spooner LM, Klibanov OM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. *Ann Pharmacother* 2012;46:1671-7.
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. *Ann Pharmacother* 2012;46:240-7.
- Griffiths CL, Olin JL. Triple negative breast cancer: a brief review of its characteristics and treatment options. *J Pharm Pract* 2012;25:319-23.
- Toussaint KA, Watson K, Marrs JC, Sturpe DA, Anderson SL, Haines ST. Prevalence of and factors that influence board certification among pharmacy practice faculty at United States colleges and schools of pharmacy. *Pharmacotherapy* 2013;33:105-11.
- Vande Griend JP, Anderson SL. Histamine₁ receptor antagonism for the treatment of insomnia. *J Am Pharm Assoc* 2012;52:e210-9.

- Woytowish MR, Maynor LM. Clinical relevance of linezolid-associated serotonin toxicity (March). *Ann Pharmacother*. 2013 Feb 19. www.theannals.com/content/early/2013/02/19/aph.1R386.abstract.html.
- Karaoui L, Chahine E, El-Lababidi R. Oritavancin: a novel lipoglycopeptide antibiotic. *Am J Health Syst Pharm* 2013;70:23-33.

New ACCP Fellows

- Shareen El-Ibiary, Pharm.D., BCPS; Midwestern University College of Pharmacy-Glendale.
- Brian A. Hemstreet, Pharm.D., BCPS; University of Colorado – Denver.
- Julie A. Murphy, Pharm.D., BCPS; The University of Toledo.

Other Notable Achievements

Amy Skiff, Pharm.D., BCPS, received BCPS certification.

Ambulatory Care PRN

Promotions

- Kelly Rudd was promoted to the clinical pharmacology service coordinator at the Bassett Medical Center in Cooperstown, New York; she also serves as regional coordinator of anticoagulation services there.
- Eric Ip of Touro University California College of Pharmacy was promoted to associate professor.

Awards

- Krystal Edwards was awarded the Texas Tech University Health Sciences Center President's Outstanding Clinician Award in fall 2012.
- Eric MacLaughlin was awarded the Texas Tech University Health Sciences Center President's Excellence in Teaching Award in fall 2012.
- Eric Ip was named the 2012 Touro University California College of Pharmacy Professor of the Year.

Grants

- Thurston MM, Huang V, Ryan GJ, Huston SA, Bourg CA, Phillips BB, Haomiao J. Impact of Health Literacy on Aspects of Medication Nonadherence Reported by Underserved Patients with Type 2 Diabetes. 2012 ACCP Ambulatory Care PRN seed grant, \$1547.60
- Dave Dixon (VCU) received a grant (\$800) from the VCU Center for Teaching Excellence: Use of Video

Recorded Clinic Visits to Improve Assessment of Pharmacy Student Clinical Interviewing Skills. He received a resource development award of \$2000 from the Association of American Medical Colleges and Interprofessional Education Collaborative for developing an Interprofessional Team-Based Learning Module on Anticoagulation.

- Martin Bishop received one of the 2012–2013 ASHP R&E Foundation Resident Research Grants (up to \$5000).
- Eric Ip as principal investigator was awarded a \$3400+ intramural \$3400+ grant for a project titled “Survey of Patient Acetaminophen Knowledge and the Impact of a Condensed Educational Consultation” by the Touro University California.
- Edith Nutescu, Pharm.D., FCCP, clinical professor at the University of Illinois College of Pharmacy, Department of Pharmacy Practice and Center for Pharmacoepidemiology and Pharmaco-economic Research, was awarded a 4-year K23 grant from the National Institutes of Health/National Heart Lung and Blood Institute to study health disparities and factors influencing adoption and feasibility of anticoagulation self-monitoring in minority underserved patients. Other UIC investigators on the project were Marian Fitzgibbon, Ph.D.; Ben Gerber, M.D., MPH; Lisa Sharp, Ph.D.; Thomas Stamos, M.D.; and Michael Berbaum, Ph.D. Additional collaborators include David Meltzer, M.D., Ph.D., from the University of Chicago and Elaine Hylek, M.D., MPH, from Boston University.
- Melanie Claborn and colleagues received a \$5000 grant from the National Association of Chain Drug Stores Foundation for the Million Hearts Initiative by University of Arkansas for Medical Sciences College of Pharmacy-Northwest – Scott Warmack, Melanie Claborn, Victoria Seaton, Eleanor Hughes, Leslie Hitt.

Publications

- Phillips BB, Thurston MM. Osteoporosis. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT, eds. *Pharmacotherapy Principles & Practice*, 3rd ed. New York: McGraw-Hill, January 2013.
- Dixon DL, Lyles A, Sicut BL, Lee B, Rybarczyk B, Lord B. Interprofessional Team-Based Learning Module: Anticoagulation. *MedEdPORTAL* 2013. Available at www.mededportal.org/publication/9334. Accessed April 6, 2013.
- Siskey J, Lyles A, Dixon DL. Beta-blockers and hypertension: where are the data? *Arch Intern Med*

2012;172:1406-12. iForumRx.org. Available at iforumrx.com/index.php?q=node/136.

- Coles T, Dixon DL. Another bust for omega-3 fatty acids – it's time to go fishing elsewhere. *N Engl J Med* 2012;367:309-18. iForumRx.org. Available at iforumrx.org/index.php?q=node/131.
- Essex MN, O'Connell M, Bhadra P. Response to nonsteroidal anti-inflammatory drugs in African Americans with osteoarthritis of the knee. *J Int Med Res* 2012;40:2251-66.
- White RR, Nickerson-Troy JA. Preventive medicine and wellness promotion. In: Dong B, Elliot D, eds. *Ambulatory Care Self-Assessment Program, 2013 Book I. Pulmonary and Preventive Care*. Lenexa, KS: American College of Clinical Pharmacy, 2013:119-33.
- Rudd KM, Phillips EL. New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. *Thrombosis*. Accepted for publication January 31, 2013.
- Hiteshew KJ, Franz T, Lamberjack K, Chen AMH. Don't leave without them: dispensing asthma medications to pediatric patients upon discharge is associated with decreased hospital readmissions. *Innov Pharm* 2012;3:Article 2.
- Bourg CA, Grigg E, May DW. Peptic ulcer disease. In: Chisholm MA, Schwinghammer TL, Wells BG, DiPiro JT, Kolesar JM, Malone PM, eds. *Pharmacotherapy Principles & Practice, 3rd ed*. New York: McGraw-Hill, 2013.
- Soric MM, ed. *Maximize Your Rotations: ASHP's Student Guide to IPPEs, APPEs, and Beyond*. Bethesda, MD: American Society of Health-System Pharmacists, 2013.
- Yu J, Shah BM, Ip EJ, Chan J. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. *J Manage Care Pharm* 2013;19:102-14.
- Ip EJ, Bui QV, Barnett MJ, Kazani A, Wright R, Serino MJ, Perry PJ. The effect of trazodone on standardized field sobriety tests. *Pharmacotherapy*. 2013 Feb 28.
- Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. The psychological and physical impact of anabolic-androgenic steroid (AAS) dependence: a comparison of AAS-dependent users and AAS-non-dependent users. *Pharmacotherapy* 2012;32:910-9.

- Truong HB, Ip EJ. A review of erythropoietin abuse: an analysis of effectiveness and safety in exercise. *J Sports Med Doping Stud* 2012;2:106.

Other Notable Achievements

- Christina Madison was named 2013 president of Nevada Public Health Association (she is one of only two pharmacists in the country to hold this type of position).
- Maria Thurston was awarded the 2012 Outstanding Young Health-System Pharmacist, Georgia Society of Health-System Pharmacists.
- Dave Dixon (VCU) passed the examination for certification as a Clinical Lipid Specialist (CLS) and was awarded Diplomate status with the Accreditation Council for Clinical Lipidology.
- Margaret Noyes Essex and colleagues presented abstracts at the American College of Gastroenterology (ACG) 77th Annual Scientific Meeting; October 19–24, 2012; Las Vegas, NV (Joshi A, Margolis M, Cappelleri J, Hsieh R, Noyes Essex M, Park P, Coyne K. Factors associated with gastroprotective agent use and adherence among adults with arthritis taking NSAIDs in the United States) and at the American College of Rheumatology (ACR); November 9–14, 2012; Washington, DC (Sands GS, Bhadra P, Noyes Essex M. The effect of age on the number of osteoarthritis flares with continuous versus intermittent celecoxib treatment).
- Mary Parker was installed as the North Carolina Association of Pharmacists president for 2013.
- Kelly Rudd was elected as president-elect of the NYS ACCP Chapter and appointed as an IPRO Anticoagulation Coalition Steering Committee member.
- Rachel Selinger attained her CDE and is now the sole CDE of any department at the UNC Chapel Hill's Campus Health Services.
- Catherine Bourg and Beth Phillips of the University of Georgia COP delivered a presentation at this year's ASHP Midyear Clinical Meeting, titled "Workshop: Evaluating Your Interviewing Skills," as part of their student programming.
- Jennie Broders was accepted into the Society of Teachers of Family Medicine Emerging Leaders program.
- Bob Talbert was the speaker for the March Rho Chi banquet for the University of Kentucky.

- Edith Nutescu, Pharm.D., FCCP, clinical professor at the University of Illinois College of Pharmacy, Department of Pharmacy Practice, and Center for Pharmacoepidemiology and Pharmaco-economic Research, was quoted in a [Nature.com](http://www.nature.com) story about new blood thinners that are arriving on the market and how they compare in effectiveness with warfarin, a popular older anticoagulant antidote.

Cardiology PRN

The ACCP Cardiology PRN has recently been focused on our role delineation survey for the consideration of cardiology as a separate certification from the Board of Pharmacy Specialties. In addition, we have focused on developing our fundraising efforts to ensure that the withdrawal of industry support does not hinder our ability to fund seed grants, student/resident travel awards, or various other important projects for our PRN.

Promotions

- **Tina Denetclaw** advanced to clinical professor, Department of Clinical Pharmacy, School of Pharmacy, University of California – San Francisco.
- **Craig R. Lee** was promoted to associate professor of pharmacy (with tenure), Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy.

Awards

- **Sarah Gaffney** received the 2012 Virginia Society of Health-System Pharmacists Clinical Pharmacy Practice Achievement Award.

Grants

- **Johnson SG.** Pharmacy Resident Practice-Based Research Grant for CYP2C19 Pilot Study. ASHP Research and Education Foundation. Role: Senior investigator.
- **Tisdale JE.** Sensitivity to drug-induced QT-interval lengthening in patients with heart failure with preserved left ventricular ejection fraction. Center of Excellence in Cardiovascular Research (CECARE), Indiana Clinical Translational Sciences Institute (CTSI), Indiana University (IU) School of Medicine, and IU Health. \$160,000. November 1, 2012 – October 31, 2014. Role: Principal investigator.

Publications

- O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM,

Franklin BA, Granger CB, Krumholz MH, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, **Ou N**, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo RY, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;61:e78-140.

- Adams AS, Uratsu C, Dyer W, Magid D, O’Conner P, Beck A, **Butler MG**, Ho M, Schmittiel J. Antihypertensive adherence among a diverse cohort of newly treated patients. *Arch Intern Med* 2012;10:1-8.
- Byrd JB, Powers JD, Magid DJ, Tavel H, Schmittiel J, O’Connor P, Margolis K, Beck A, **Butler MG**, Ho M. Detection and recognition of hypertension in anxious and depressed patients. *J Hypertens* 2012;30:2293-8.
- **Chow SL.** Heart failure with preserved ejection fraction. In: Murphy J, Lee M, eds. *Pharmacotherapy Self-Assessment Program*, 8th ed. Book 2. Cardiology and Endocrinology. Lenexa, KS: American College of Clinical Pharmacy, 2013:153-72.
- Wang JSC, Kovanecz I, Vernet D, Nolzco G, Kopchok GE, **Chow SL**, White RA, Gonzalez-Cadavid NF. Effects of sildenafil and/or muscle-derived stem cells on myocardial infarction. *J Transl Med* 2012;10:1-11.
- LaForest SK, **Chow SL**, **DiDomenico R**, Dracup K, **Ensor C**, Gattis-Stough W, Heywood JT, Lindenfeld J, **Page RL**, Patterson JH, **Vardeny O**, Massie BM. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. In press. Co-publication in *Journal of Cardiac Failure and Pharmacotherapy*, April 2013.
- **Johnson SG.** Clinical pharmacogenomics: potential impact on cardiovascular disease outcomes. In: Page RL, Murphy JM, et al., eds. *Pharmacotherapy Self-Assessment Program*, 8th ed. Lenexa, KS: American College of Clinical Pharmacy, 2013.
- **Dobesh PP, Beavers CJ, Herring HR, Spinler SA, Stacey ZA, Trujillo TC.** Key articles and guidelines in the management of acute coronary syndrome and in percutaneous coronary intervention: 2012 update. *Pharmacotherapy* 2012;32:e348-86.
- Stover R, Lane MA, Gokun Y, Elayi SC, Macaulay TE, **Beavers CJ**, Knight J. Sotalol versus amiodarone in atrial arrhythmias: impact of renal insufficiency

and ejection fraction. ASHP Annual Midyear Meeting; 2012; Las Vegas, NV.

- **Tisdale JE.** Arrhythmias. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT, eds. *Pharmacotherapy Principles & Practice*, 3rd ed. New York: McGraw-Hill, 2013:169-95.
- Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, **Tisdale JE**, Overholser BR. Pharmacokinetic modeling and simulation of procainamide and *N*-acetylprocainamide in a patient receiving CRRT: a novel approach to guide renal dose adjustments. *Am J Kidney Dis* 2013. In press.
- **Hollands JM**, Gowan M, Riney JN, Deal EN, Kates AM. Role of new drugs for management of atrial fibrillation. *Ann Pharmacother* 2012;46:1656-70.
- **Lalama J.** Arrhythmias. In: Attridge RL, Miller ML, Moote R, Ryan L, eds. *Internal Medicine: A Guide to Clinical Therapeutics*. New York: McGraw-Hill, 2013:25.
- **Lalama J**, Lewis PM, Gore J, Tran MT, Donovan J. How one academic medical center has managed potency changes with unfractionated heparin. *J Thromb Thrombolysis*. 2012. [Epub ahead of print]
- **Young SK, Riding D, Antonio ME, Al-Mondhiry MA.** Efficacy of a nurse-managed argatroban dose-adjustment protocol in a university teaching hospital. *Hosp Pharm* 2012;47:712-20.
- **McConnell KJ, Shaw PB.** Cardiovascular complications in patients with diabetes. In: Murphy J, Lee M, eds. *Pharmacotherapy Self-Assessment Program*, 2013 Book 1. Cardiology and Endocrinology. Lenexa, KS: American College of Clinical Pharmacy, 2013:25-48.
- **McConnell KJ**, Delate T, Newlon CL. Impact of continuing professional development versus traditional continuing pharmacy education on learning behaviors. *J Am Pharm Assoc* 2012;52:742-52.
- Sobieraj DM, White WB, **Baker WL.** Cardiovascular effects of pharmacologic therapies for smoking cessation. *J Am Soc Hypertens* 2013;7:61-7.
- **Baker WL, Marrs JC, Davis LE, Nutescu EA, Rowe AS, Ryan M, Splinter MY, Vardeny O, Fagan SC.** Key articles and guidelines in the primary prevention of ischemic stroke. *Pharmacotherapy*. 2013 Feb 11.
- **Baker WL, Marrs JC, Davis LE, Nutescu EA, Rowe AS, Ryan M, Splinter MY, Vardeny O, Fagan SC.** Key articles and guidelines in the acute management

and secondary prevention of ischemic stroke. *Pharmacotherapy*. 2013 Feb 11.

- **Denetclaw TH**, Cefalu P, Manila LL, Panagotacos JJ. Needs analysis for educating community pharmacists to interface with prehospital stroke chain of survival. *J Stroke Cerebrovasc Dis* 2012. pii: S1052-3057(12)00382-5.
- Theken KN, Schuck RN, Edin ML, Tran B, Ellis K, Bass A, Lih FB, Tomer KB, Poloyac SM, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA, **Lee CR.** Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. *Atherosclerosis* 2012;222:530-6.
- Marczak ED, Marzec J, Zeldin DC, Kleeberger SR, Brown NJ, Pretorius M, **Lee CR.** Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. *Pharmacogenet Genomics* 2012;22:620-8.
- Crossman S, Stevens M, Ryan M, Mack D, **Dixon D.** Interprofessional global service learning through HOMBRE (Honduras Outreach Medical Brigade Relief Effort). Presented at: Jewell and Carol Emswiller Interprofessional Symposium; 2013; Richmond, VA.
- **Dixon DL**, Lyles A, Sicat BL, Lee B, Rybarczyk B, Lord B. Interprofessional Team-Based Learning Module: Anticoagulation. *MedEdPORTAL* 2013. Available at www.mededportal.org/publication/.
- Siskey J, Lyles A, **Dixon DL.** Beta-blockers and hypertension: where are the data? *Arch Intern Med* 2012;172:1406-12. [iForumRx.org](http://iforumrx.org). Available at iforumrx.com/index.php?q=node/136.

Other Notable Achievements

Sheryl L. Chow: Elected as Fellow of the American Heart Association (FAHA).

Samuel G. Johnson:

- Appointed to the ACCP Task Force on Practice Innovation, 2012–2013.
- Appointed as Faculty Panel Chair (Cardiology Book) for the Ambulatory Care Self-Assessment Program (ACSAP) (Dong B, Elliott D, eds.).
- Installed as inaugural Institute of Medicine Anniversary Fellow in Pharmacy, 2012–2014.

Craig Beavers: Beginning a 3-year council position on the Cardiovascular Team Council for the American College of Cardiology Foundation.

Barbara Wiggins:

- Asked to serve on the Editorial Board of Clinical Cardiovascular Drugs.
- Appointed to the Council on Clinical Practice of the American College of Cardiology.

Mary Parker: Installed in October as the 2013 president of the North Carolina Association of Pharmacists.

Augustus (Rob) Hough and **David Parra:** Developed and released a tutorial and interactive smartphone (iPhone/iPad, Android) application on using plasma renin activity to guide antihypertensive therapy. The application software, which is available to the public free of charge, can be accessed at itunes.apple.com/us/app/prn-and-htn/id601765986?mt=8 for the iPhone/iPad.

Dave L. Dixon:

Passed the examination for certification as a Clinical Lipid Specialist (CLS), and he was awarded Diplomate status with the Accreditation Council for Clinical Lipidology.

Received a resource development award of \$2000 from the Association of American Medical Colleges and Interprofessional Education Collaborative for developing an Interprofessional Team-Based Learning Module on Anticoagulation.

Central Nervous System PRN

Publications

- **Chen JJ**, Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. *Pharmacotherapy* 2013;33:304-18.
- Leppik IE, **Hovinga CA**. Extended-release anti-epileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. *Epilepsia* 2013;54:28-35.
- Baker WL, Marrs JC, Davis LE, Nutescu EA, **Rowe AS**, **Ryan M**, **Splinter MY**, Vardeny O, **Fagan SC**. Key articles and guidelines in the primary prevention of ischemic stroke. *Pharmacotherapy* 2013. (doi: 10.1002/phar.1255)
- Baker WL, Marrs JC, Davis LE, Nutescu EA, **Rowe AS**, **Ryan M**, **Splinter MY**, Vardeny O, **Fagan SC**. Key articles and guidelines in the acute management and secondary prevention of ischemic stroke. *Pharmacotherapy* 2013. (doi: 10.1002/phar.1252)

Clinical Administration PRN

The Clinical Administration PRN continues to grow (now at 387 members) and is actively pursuing a list of endeavors for 2013. The Programming/Focus Session Committee is working to address one of the main concerns voiced by members in our most recent survey. The program is titled “Advancing the Pharmacy Practice Model Through Effective Staff Development Strategies.”

The Research and Scholarship Committee is working on an application for a scholarship for students or residents to travel to the ACCP Annual Meeting and possibly to reimburse some BPS examinations. Students are requesting a more active role in the PRN. This year was no exception, with three students and one resident attending the PRN meeting. It is exciting to see recent graduates excited about leadership in the clinical administration arena. The PRN is excited to continue developing young leaders through involvement in activities of the PRN.

The PRN has renewed dialogue with the Leadership Academy and is actively engaged in seeking topics, editors, and names of potential speakers for the Academy Newsletter and Certificate Program.

Notable Achievements

- **John Noviasky**, Pharm.D., BCPS, clinical coordinator at Upstate University Hospital at Community General. Since transitioning to this position, he has opened two pharmacy satellites, is cochair of the Pharmacy and Therapeutics Committee, and actively rounds with hospitalists. Dr. Noviasky also recently published an article titled “Effectiveness of Sodium Polystyrene Sulfonate in Decreasing Serum Potassium” in the *International Journal of Nephrology and Renovascular Disease*, vol 2012; Article ID 940320.
- **Kenneth Komorny**, Pharm.D., BCPS; **Mary Hailer**, Pharm.D., BCPS; and **Maria Giannakos**, Pharm.D., MBA, BCPS, from Summa Health System all received their Lean Six Sigma Green Belt Certifications. Their project was related to pharmacy-managed warfarin consults and development of an Antimicrobial Stewardship Team.
- **Andrea Chbeir**, Pharm.D., BCPS, clinical coordinator at Blessing Hospital, completed the Society of Infectious Diseases Pharmacists (SIDP) Antimicrobial Stewardship Certificate Program. In addition, six of her direct reports completed the program.
- **Harminder Sikand**, Pharm.D., FCSHP, FASHP, clinical director and residency director at Scripps Mercy Hospital, was recently elected as president of the San Diego Society of Health-System Pharmacists.

Critical Care PRN

Update: Issues of Interest to Membership

Provided by: Curtis Haas, Pharm.D., BCPS; and Stacy Voils, Pharm.D., BCPS

BPS Approves Critical Care Pharmacy as New Specialty

BPS has announced the approval of critical care pharmacy as a new specialty. The approval of pediatric pharmacy as a specialty was announced at the same time (see related article on page 3). As most of you know, BPS conducted a role delineation study of critical care pharmacy practice and subsequently issued a request for petition last year. ACCP, ASHP, and APhA collaborated on developing the petition that was submitted to BPS in November 2012. BPS held open hearings regarding the petition at the Midyear Clinical Meeting, a transcript of which is available at the BPS Web site (www.bpsweb.org/specialties/criticalcarepharmacy.cfm).

Medicare benefit initiative to recognize clinical pharmacists' direct patient care services ("provider status")

Last December, ACCP announced the launch of a formal initiative to pursue recognition of direct patient care (DPC) services by clinical pharmacists as a covered benefit under the Medicare program (www.accp.com/report/?iss=1212&art=1). The framework of this initiative should resonate well with critical care pharmacists because it is focused on DPC (assessment of patients and their pharmacotherapy needs; initiation, modification, or discontinuation of patient-specific drug therapy; and ongoing monitoring and follow-up) as members of a team providing interdisciplinary patient care. This is the essence of the model of the clinical pharmacist's role as a member of the critical care patient care team, which the specialty has embraced for more than 2 decades. As our health care delivery system evolves under health care reform, it is more important than ever that clinical pharmacy and the value we bring to patient care are recognized by CMS (Centers for Medicare & Medicaid Services) and other payers. Because fee-for-service reimbursement, as we know it, is going away, it is difficult to know what might evolve as the financial impact of "provider status," but it is important that clinical pharmacy have a "seat at the table" in a reformed system of health care delivery. It is also imperative that we articulate that this initiative is not about pharmacy or pharmacists, but about patients. We believe the active engagement of clinical pharmacists on the patient care team improves quality and outcomes by "getting the medications right."

ACCP has retained the Federal Group, a Washington

consulting firm with a track record in lobbying, for provider recognition. The Federal Group will provide strategic government relations and advocacy services to assist ACCP in pursuing this goal. It will be a potentially long and challenging path to travel, but ACCP has defined this as our most important policy and advocacy agenda item. Please take a few minutes and read the related articles in the December and January *ACCP Reports*, which include an FAQ document to help clearly define the goals and principles underlying this effort.

Student Chapter Recognition

For those of you in academia (or students), the Board of Regents made an important announcement after the October board meeting. ACCP has decided to create a mechanism for the formal recognition of student chapters. Students make up the fastest-growing membership category in ACCP, and the student members have made it clear to the board that recognition of student chapters on school campuses is very important to them. At the request of the Board of Regents, ACCP staff are currently working on the details of chapter recognition, which should be made public sometime later this year, together with the time line for implementation. This creates an exciting opportunity to spread the word about the benefits of ACCP membership to more students and to offer options for local engagement in a chapter of a national pharmacy organization that is focused on developing, advancing, and positioning clinical pharmacists. The number of student chapters is expected to increase steadily in the next few years, which will further promote the growth of our student membership. This is not only great for the current vitality of the organization, but is also an investment in the future of the organization and the discipline of clinical pharmacy.

Awards

Congratulations to the recipients of the following awards, presented at the 2012 ACCP Annual Meeting.

- **Asad (Sid) Patanwala, Pharm.D., BCPS:** ACCP New Clinical Practitioner Award
- **Ishaq Lat, Pharm.D., FCCP, FCCM, BCPS:** Critical Care PRN Education Award
- **Douglas Fish, Pharm.D., FCCP, FCCM:** Critical Care PRN Research Award
- **Alley Killian, Pharm.D., BCPS:** Critical Care PRN Clinical Practitioner Award
- **Judith Jacobi, Pharm.D., FCCP, FCCM, BCPS, DPNAP:** Critical Care PRN Achievement Award

- **Sara Jordan, Pharm.D.:** Critical Care PRN Young Investigator Travel Award
- **Bryan Lizza, Pharm.D.:** Critical Care PRN Resident/Fellow Travel Award

New Committee Update

Provided by: Pamela Smithburger, Pharm.D., BCPS

During the 2012 ACCP Annual Meeting in Hollywood, Florida, the PRN membership voted to create a newly formed research committee. The newly formed research committee's charges include (1) developing a funding mechanism to support a Critical Care PRN member's participation in the ACCP FIT program, (2) developing and implementing a PGY2 research grant, and (3) developing and implementing a Critical Care PRN Member Research Grant. Those who are interested in helping to complete the charges of the new committee or those with questions can contact Pam Smithburger by e-mail (smithburgerpl@upmc.edu).

Drug Information PRN

Awards

- **May DW,** Norman C, Gomez TA. Outstanding Health-System Newsletter Award. Georgia Society of Health-System Pharmacists; October 2012; Young Harris, GA.

Grants

- **Freeman MK, Hughes PJ, Slaton RM.** Samford University Global Drug Information Service – Birmingham, Alabama.;
 - **Alabama Alliance for Nursing Facility Quality and Care Coordination – Funding Opportunity No. CMS-1E1-12-002** [Initiative to Reduce Avoidable Hospitalizations Among Nursing Facility Residents]. U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Medicare and Medicaid Coordination Office, Center for Medicare & Medicaid Innovation. Collaboration with Alabama Quality Assurance Foundation (AQAF), The University of Alabama at Birmingham, Samford University, and Alabama Department of Senior Services. Principal investigator: Liz Prosch, RN, MSHA, LNHA. Status: Funded
Role: Coinvestigators
Grant Amount: \$15,000,000. September 2012
- **Gettig JP.** 1st Annual Update in Diabetes Management and Education. Submitted to Amylin

Pharmaceuticals for \$10,250. Awarded \$5000. February 2012.

- **Gettig JP.** 1st Annual Updates in Diabetes Management and Education. Submitted to Novo Nordisk, Inc., for \$10,250. Awarded \$7500. February 2012.
- **Gettig JP.** 1st Annual Updates in Diabetes Management and Education. Submitted to Merck & Co., Inc., for \$10,250. Awarded \$5000. February 2012.
- **Ward K.** Addressing Educational and Coordination Barriers for Adult Pneumococcal Disease Prevention in Rhode Island.
Role: Coinvestigator
Funding Source: Pfizer Medical Education Group
Funding Amount: \$703,993

Publications

- **Cole SW,** Lundquist LM. Icatibant for the treatment of hereditary angioedema. *Ann Pharmacother* 2013;47:49-55.
- Shannon JA, **Cole SW.** Pegloticase: a novel agent for treatment-refractory gout. *Ann Pharmacother* 2012;46:368-76.
- Lundquist LM, **Cole SW,** Augustine JM. Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis. *Open Access Rheumatol Res Rev* 2012;4:9-19.
- Forehand CF, Cribb J, **May JR.** Examination of the relationship between antimicrobials and thrombocytosis. *Ann Pharmacother* 2012;46:1425-9.
- **Fox ER,** Tyler LS. Call to action: finding solutions for the drug shortage crisis in the United States. *Clin Pharmacol Ther* 2013;93:145-7.
- **Gabay MP,** Thakkar JP, **Stachnik JM,** Woelich SK, Villano JL. Intra-CSF administration of chemotherapy medications. *Cancer Chemother Pharmacol* 2012;70:1-15.
- **Gabay M.** Tech-check-tech: an overview. *Hosp Pharm* 2012;47:444-5.
- **Gabay M.** Drug importation: where do we stand? *Hosp Pharm* 2012;47:110-1.
- Freeland KN, Cogdill BR, Ross CA, Sullivan CO, Drayton SJ, VandenBerg AM, Short EB, **Garrison KL.** Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting. *J Health Syst Pharm Res.* 2012;1(1). Available online.

- Miller D, Garcia D, Jade-Kreys T, Phan S, VandenBerg A, **Garrison KL**. Evaluation of the quality of medication reconciliation obtained upon hospital admission. *Hosp Pharm* 2012;47:526-31.
- **Gettig JP**. Application process – the holiday rush. In: Bookstaver PB, Caulder CR, Smith KM, et al. *Roadmap to Postgraduate Training in Pharmacy*. New York: McGraw-Hill, 2013:139-61.
- **Giouroukakis M**, Dryer M. Unapproved drugs—the drug information pharmacists’ perspective. *J Pharm Pract*. 2013 Mar 4.
- Shepherd G, Mohorn P, Yacoub K, **May DW**. Adverse drug reaction deaths reported in United States vital statistics, 1999-2006. *Ann Pharmacother* 2012;46:169-75.
- Cooley TW, **May DW** (corresponding author), Alwan M, Sue C. Implementation of computerized prescriber order entry in four academic medical centers. *Am J Health Syst Pharm* 2012;69:2166-4.
- **May DW**, Chisholm-Burns MA. Gastroesophageal reflux disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT, eds. *Pharmacotherapy Principles & Practice*, 3rd ed. New York: McGraw-Hill, 2013:333-44.
- Bourg CA, Gregg EL, **May DW**. Peptic ulcer disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, DiPiro JT, eds. *Pharmacotherapy Principles & Practice*, 3rd ed. New York: McGraw-Hill, 2013:345-58.
- **May JR**, Chan J, Choudhary K, et al. Coping with the residency scramble. *Am J Health Syst Pharm* 2012;69:253-5.
- **May JR**, Smith PH. Drug allergies and pseudoallergies. In: *Pharmacotherapy Principles & Practice*, 3rd ed. New York: McGraw-Hill, 2013:965-76.
- **Phillips JA, Gabay MP, Ficzer C, Ward KE**. Curriculum and instructional methods for drug information, literature evaluation, and biostatistics: a survey of US pharmacy schools. *Ann Pharmacother* 2012;46:793-801.

Other Notable Achievements

- **Gettig JP**. Selected as a fellow in the AACP Academic Leadership Fellows Program (ALFP) for 2012–2013.
- **May JR**. Presented the following topics at the Clinical Symposium, Misr International University; November 2012; Cairo, Egypt:

- “Foundations of Antimicrobial Stewardship”
- “New Drug Update 2012: A Formulary Approach”
- **May JR, May DW**. Conducted “Systematic Approach to Drug Information,” a 4.5-hour workshop for hospital pharmacists at Misr International University. This workshop was in response to the Egyptian Ministry of Health’s decision to make drug information centers in Egyptian hospitals mandatory.
- **May JR**. Worked with University of Georgia College of Pharmacy students to establish the Student Diabetes Club as an official organization at the university. Named faculty adviser for the organization. A drug information newsletter for diabetes called *Diabetes in Focus* is the official publication for this group.
- **Cole SW**, Hanrahan CT. Assessment of drug information resource preferences by pharmacy students and faculty [abstract 48]. *Pharmacotherapy* 2012;32:e191. [Poster Presentation]

Education and Training PRN

The Education and Training PRN (EDTR) has grown to more than 450 members who continue to advance the PRN’s mission of promoting dialogue and interaction to develop programs that enhance the knowledge and skills needed to provide education and training within clinical pharmacy. The PRN is happy to share the many accomplishments of its members and looks forward to another productive year.

The EDTR once again hosted the mock interviews for students and residents during the 2012 ACCP Annual Meeting. Sixty interviewees took advantage of this opportunity to learn key interviewing skills from clinical faculty and practitioners in preparation for residency or initial career position interviews. Forty-two interviewers graciously volunteered their time to make this event a success. Most participants were able to go through two or three rounds of mock interviews to receive valuable feedback from several interviewers.

During the EDTR business meeting, members also had the opportunity to hear from Janet Teeters, director of accreditation services at ASHP, who provided a very informative update regarding changes to pharmacy-specific duty hours, board certification required for PGY2 residency program directors, the post-Match process, and PhORCAS (Pharmacy Online Residency Centralized Application).

Our Scholarly Activities Committee is continuing its work on a book that will offer useful teaching tips for clinical faculty and preceptors. A special thanks to Tina Denetclaw for her continued leadership on this important project.

At the upcoming ACCP Spring Updates in Therapeutics® meeting in Reno, Nevada, the EDTR will host a networking breakfast on Sunday, April 21, from 7:30 a.m. to 9:00 a.m. This will provide a good opportunity to meet informally with other PRN members to exchange ideas related to teaching and learning.

The EDTR is proud of its growing membership and would like to continue expanding. We encourage ACCP members who are interested in promoting our mission to join the EDTR PRN.

Promotions

Haley Phillippe, Pharm.D., BCPS: Dr. Phillippe will be promoted to associate clinical professor at Auburn University Harrison School of Pharmacy (AUHSOP) in the fall.

T. Lynn Stevenson, Pharm.D., BCPS: Dr. Stevenson will be promoted to associate clinical professor at Auburn University Harrison School of Pharmacy (AUHSOP) in the fall.

Awards

Katie S. McClendon, Pharm.D., BCPS, was honored by the Mississippi Board of Trustees of State Institutions of Higher Learning as the University of Mississippi Medical Center's 2013 Diversity Educator of the Year.

Grants

Rebecca B. Sleeper Irons, Pharm.D., FCCP, FASCP, BCPS, received a grant (\$25,000) from the Laura Bush Institute for Women's Health for the initial phase of a collaboration between the schools of pharmacy, nursing, and medicine to audit and map existing curricular content/delivery related to sex- or gender-based medicine at Texas Tech University Health Sciences Center (TTUHSC) with the goal of evaluating and enhancing the delivery of gender-specific content in health professions curricula.

Samantha Karr, Pharm.D., BCPS, BCACP, was awarded an intramural grant by the Midwestern University College of Pharmacy-Glendale for \$2830 for research titled, "Assessing Accuracy and Impact on Clinical Decision-making of Community-Based Blood Pressure Monitoring."

Publications

Michael J. Peeters, Pharm.D., M.Ed., BCPS
Vaidya V, **Peeters MJ,** Partha G, Potnis P. Evaluating the association between type of prescription drug plan and asthma patients' use of controller medications. *J Pharm Health Serv Res* 2012;3:65-9.

Serres ML, **Peeters MJ.** Overcoming content specificity in admission interviews: the next generation? *Am J Pharm Educ* 2012;76:Article 207.

Gundrum TE, Serres ML, **Peeters MJ.** Reliability of an approach to pharmacy resident selection. Abstract presented at: ASHP Midyear Meeting; December 5, 2012; Las Vegas, NV.

Peeters MJ, Cox CD. A pilot in peer observation of clinical teaching. Abstract presented at: Conference Proceedings of the Professional and Organizational Development Network; 2012.

Hoover M, Jacobs D, Jung R, **Peeters MJ.** Validity and reliability with educational testing in the pharmacy and medical literature [abstract]. *Pharmacotherapy* 2012;32(10).

Sarah A. Nisly, Pharm.D., BCPS

Nisly SA, Kolanczyk D, Walton AM. Canagliflozin, a new sodium-glucose co-transporter 2 inhibitor, in the treatment of diabetes. *AJHP* 2013;70:311-9.

Axford K, Dy E, **Nisly SA.** Lipid goals: update on their status. *Indiana Pharmacists Alliance (IPA) continuing pharmacy education (CPE).* 2012;8:1-8.

Katie S. McClendon, Pharm.D., BCPS

McClendon KS. Phentermine/topiramate ER (Qsymia): second new obesity medication approved in 2012 [update]. In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. *Pharmacotherapy: A Pathophysiologic Approach*, 8th ed. New York: McGraw-Hill, 2012. www.accesspharmacy.com/updatesContent.aspx?aid=4000240.

McClendon KS. Lorcaserin approved for treatment of obesity [update]. In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. *Pharmacotherapy: A Pathophysiologic Approach*, 8th ed. New York: McGraw-Hill, 2012. www.accesspharmacy.com/updatesContent.aspx?aid=4000198.

Amy Tiemeier, Pharm.D., BCPS

Grice GR, Gattas NM, Sailors J, Murphy JA, **Tiemeier AM,** Hurd P, Prosser T, Berry T, Duncan W. Health literacy: use of the Four Habits Model to improve student pharmacists' communication. *Patient Educ Couns* 2013;90:23-8.

Cain J, Scott DR, Metzger A, **Tiemeier AM.** Social media use by pharmacy faculty: student friending, e-professionalism, and professional use. *Curr Pharm Teach Learn* 2013;5:2-8.

Vouri SM, **Tiemeier AM.** The ins and outs of pharmacy services at a Program of All-inclusive Care for the Elderly (PACE) organization. *Consult Pharm* 2012;27:803-7.

Sandra Benavides, Pharm.D.; and **Joshua Caballero, Pharm.D., BCPP**

Caballero J, Wolowich WR, **Benavides S,** Marino J. Difficulty and discrimination indices of multiple-choice examinations in a college of pharmacy pathophysiology and therapeutics course sequence. *Int J Pharm Pract.* 2013. [Epub ahead of print]

Sandra Benavides, Pharm.D.

Dr. Benavides served as lead editor in the first pediatric textbook, *Pediatric Pharmacotherapy*, available through the ACCP Bookstore. The book includes 53 peer-reviewed chapters on common pediatric diseases. Dr. Benavides also wrote two chapters on diabetes and obesity (**Benavides S,** Nahata MC, eds. *Pediatric Pharmacotherapy*. Lenexa, KS: American College of Clinical Pharmacy, 2012).

Presentations

Beth H. Resman-Targoff, Pharm.D., FCCP

Resman-Targoff B. Their own worst enemy: helping patients with autoimmune diseases. Paper presented at: American Pharmacist Association (APhA) Annual Meeting; March 2013; Los Angeles, CA.

Lori B. Hornsby, Pharm.D., BCPS

Hornsby L. Update in venous thromboembolism. Paper presented at: Alabama Pharmacy Association Midwinter Conference; February 2013; Auburn, AL.

New ACCP Fellows

Recently inducted at the ACCP Annual Meeting in October 2012:

Amie D. Brooks, Pharm.D., BCPS (St. Louis College of Pharmacy)

Shareen El-Ibiary, Pharm.D., BCPS (Midwestern University, College of Pharmacy-Glendale)

Kristi Kelley, Pharm.D., BCPS, CDE (Auburn University, Harrison School of Pharmacy)

Julie Kissack, Pharm.D., BCPS (Harding University, College of Pharmacy)

Julie Murphy, Pharm.D., BCPS (The University of Toledo)

Susan Winkler, Pharm.D., BCPS (Midwestern University, College of Pharmacy Chicago)

Other Notable Achievements

Jennifer Clements, Pharm.D., BCPS, CDE: Dr. Clements is now an associate professor of pharmacy practice at Presbyterian College School of Pharmacy.

Lynn Radonic Patton, RPh, M.S., BCNSP: Dr. Patton is president of the Arizona Society for Parenteral and Enteral Nutrition (AzSPEN).

Christina M. Madison, Pharm.D., BCACP: Dr. Madison is serving a 1-year term as president of Nevada Public Health Association. She is one of only two pharmacists in the country to hold this position in a public health association.

Emergency Medicine PRN

Current Officers:

Chair: Nicole M. Acquisto, Pharm.D., BCPS

Chair-Elect: Mary Beth Shirk, Pharm.D., BCPS

Secretary/Treasurer: Megan Musselman, Pharm.D., BCPS

Please stop by the Emergency Medicine PRN (EMED PRN) table during the ACCP networking breakfast on Saturday, April 20, 2013, 7:30 – 9:00 a.m., at the Peppermill Resort, Reno, Nevada, as part of the series of networking breakfasts during ACCP's Updates in Therapeutics®.

The EMED PRN would like to acknowledge and congratulate all of its members on their accomplishments and achievements.

Awards

- **Zlatan Coralic, Pharm.D.:** Pharmacy Practice Residency Preceptor of the Year 2012 – University of California – San Francisco.

Grants

- **Zlatan Coralic, Pharm.D.:** ASHP Foundation 2012 New Investigator Research Grant.
- **Kevin O. Rynn, Pharm.D., FCCP, DABAT:** Awarded a \$50,000 Community Pharmacy Residency Expansion Project (PREP) grant to be distributed over 3 years from the NACDS foundation in support of residency program expansion.

Publications

Nicole M. Acquisto, Pharm.D., BCPS:

- Kamali MF, Wilson AC, **Acquisto NM,** Spillane L, Schneider SM. Acute encephalopathy with concurrent respiratory and metabolic disturbances in first known parenteral human administration of flunixin meglumine and acepromazine maleate. *J Emerg Med* 2012. Accepted for e-publication.
- Fabiano SE, **Acquisto NM.** Evaluation of methods of education for emergency medicine providers

and utilization in daily practice. Paper presented at: 47th Annual American Society of Health-System Pharmacists. Midyear Clinical Meeting and Exhibition; December 5, 2012; Las Vegas, NV.

- **Bucklin M, Rosenblum T, Crowley A, Leonhardt AM, Acquisto NM.** Effect of continuous infusion versus intermittent administration of antihypertensive medications on time to goal blood pressure in patients with acute stroke. The 47th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; December 5, 2012; Las Vegas, NV.
- **Bucklin M, Rosenblum T, Crowley A, Leonhardt AM, Acquisto NM.** Effect of continuous infusion versus intermittent administration of antihypertensive medications on time to goal blood pressure in patients with acute stroke. United HealthSystem Consortium Annual Meeting; December 2012; Las Vegas, NV.
- Groth CM, **Acquisto NM.** Pharmacists as members of the rapid response team. American College of Clinical Pharmacy Annual Meeting; October 2012; Hollywood, FL. *Pharmacotherapy* 2013;32:966.
- Phillips MA, **Acquisto NM, Gorodetsky RM, Wiegand TJ.** Physostigmine continuous infusion for the treatment of anticholinergic toxicity in combined diphenhydramine and bupropion overdose. Annual Meeting of the North American Congress of Clinical Toxicology; October 2012; Las Vegas, NV.

Katelyn R. Dervay, Pharm.D., BCPS:

- Adams D, **Dervay K.** Pharmacology of procedural sedation. *AACN Adv Crit Care* 2012;23:355-6.

Darrel W. Hughes, Pharm.D., BCPS:

- **Hughes DW, Attridge RL.** Advanced cardiac life support. In: Attridge, Miller, Moote, Ryan, eds. *Internal Medicine: A Guide to Clinical Therapeutics*. New York: McGraw-Hill, 2013.
- **Hughes DW.** Antidotes appendix. In: Attridge, Miller, Moote, Ryan, eds. *Internal Medicine: A Guide to Clinical Therapeutics*. New York: McGraw-Hill, 2013.
- Duhon B, Franco-Martinez AC, Maxwell PR, Attridge RL, **Hughes DW.** Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. *Ann Pharmacother* 2013. In press.
- Caballero GC, **Hughes DW, Gamboa C, Maxwell P, Green K, Barthol C.** Levetiracetam compared to

phenytoin for seizure prophylaxis following traumatic brain injury: a retrospective review. *Hosp Pharm* 2013. In press.

Megan Musselman, Pharm.D., BCPS:

- **Musselman M, Saely S.** Drug-induced hyperthermia: diagnosis and treatment. *Am J Health Syst Pharm* 2013;70:34-42.
- Wilson RF, Atkinson BE, Flynn LM, **Musselman M, Hall Zimmerman L.** Cardiovascular anatomy and physiology. In: Asensio, Trunkey, eds. *Current Therapy for Trauma and Critical Care*, 2nd ed. Philadelphia: Elsevier. In press.
- **Musselman M, Lucas AJ, Robke JT.** Survey assessment of pharmacy resident and preceptor perceptions of feedback. Paper presented at: 47th Annual ASHP Midyear Clinical Meeting; December 4, 2012; Las Vegas, NV.

Asad (Sid) Patanwala, Pharm.D., BCPS:

- **Patanwala AE.** PGY2-acute care medicine. In: Bookstaver et al., eds. *Roadmap to Postgraduate Training in Pharmacy*. New York: McGraw-Hill, 2013:273-85.
- Mosier J, Chiu S, **Patanwala AE, Sakles JC.** A comparison of the GlideScope video laryngoscope to the C-MAC video laryngoscope for intubation in the emergency department. *Ann Emerg Med.* 2013 Jan 29.
- **Patanwala AE, Jasiak KD, Christich AC, Edwards CJ, Phan H, Snyder EM.** Age-related differences in propofol dosing for procedural sedation in the emergency department. *J Emerg Med.* 2013 Jan 16.
- **Patanwala AE, Holmes K, Erstad BL.** Analgesic response to morphine in obese and morbidly obese patients in the emergency department. *Emerg Med J.* 2013 Jan 12.
- Amini A, **Patanwala AE, Maegawa FB, Skrepnek GH, Jie T, Gruessner RW, Ong ES.** Effect of epidural analgesia on postoperative complications following pancreaticoduodenectomy. *Am J Surg* 2012;2004:1000-4.
- Watt J, Amini A, Traylor B, Amini R, Sakles JC, **Patanwala AE.** Effect of paralytic type on time to post-intubation sedative use in the emergency department. *Emerg Med J.* 2012 Nov 8.
- Erstad BL, **Patanwala AE, Theodorou AA.** Comparison of methods for the detection of

medication safety events in the critically ill. *Curr Drug Saf* 2012;7:238-46.

Suprat Saely, Pharm.D., BCPS:

- Musselman ME, **Saely S**. Diagnosis and treatment of drug-induced hyperthermia. *Am J Health Syst Pharm* 2013;70:34-42.

Kyle Weant, Pharm.D., BCPS:

- Mason MA, **Weant KA**, Baker SN. Rapid sequence intubation medication therapies: a review in light of recent drug shortages. *Adv Emerg Nurs J* 2013;35:16-25.
- **Weant KA**, Baker SN. Review of human rabies prophylaxis and treatment. *Nurs Clin North Am* 2013. In press.
- **Weant KA**, Baker SN. Emergency medicine pharmacists and sepsis management. *J Pharm Pract* 2012. In press.
- Debrates SR, **Weant KA**, Seamon JP, Shirakbari A, Baker SN. Emergency pharmacist impact on health care-associated pneumonia empiric therapy. *J Pharm Pract* 2012. In press.
- McConeghy KW, Winstead PS, Cook AM, Martin CA, **Weant KA**, Flynn JD. Benefits of a 24-hour inhouse on-call program for pharmacy residents. *AJHP* 2012;69:2150-64.

Presentations/Posters

- **Nicole M. Acquisto, Pharm.D., BCPS:** Presented an emergency medicine clinical pearl, "Physostigmine: it's back," at the ASHP Midyear Clinical Meeting; December 5, 2012; Las Vegas, NV.
- **Craig Cocchio, Pharm.D., BCPS:** Evolving trends in the acute management of traumatic brain injury. Presented as: part of the Emergency Medicine PRN Focus Session—Traumatic Emergencies: Blood, Brain, and Bacteria. ACCP Annual Meeting; October 22, 2012; Hollywood, FL.
- **Megan Musselman, Pharm.D., BCPS:** Attack of the killer migraine: droperidol to the rescue. Presented as: ACPE CE lecture, part of the ASHP Midyear Clinical Meeting to Pharmacists, Pharmacy Residents, and Pharmacy Technicians; December 5, 2012; Las Vegas, NV. Toxicologic emergencies. Presented as an ACPE CE lecture, part of the KCHP/MSHP Annual Meeting to Pharmacists, Pharmacy

Residents, and Pharmacy Technicians; April 20, 2012; Kansas City, MO.

- **Suprat Saely, Pharm.D., BCPS:** Moore D, **Saely S**, Jennett-Reznek AM, Courage CA, Sherwin RL. Short-term use of neuromuscular blocking agents in post rapid sequence intubation patients are not harmful, and may be beneficial! Paper presented at: American College of Emergency Physicians Research Forum; October 8, 2012; Denver, CO.
- Kwiatkowski GM, **Saely S**, Purakal J, Mahajan A, Levy PD. Nitroglycerin for treatment of acute, hypertensive heart failure: bolus, drip or both? Paper presented at: American College of Emergency Physicians Research Forum; October 9, 2012; Denver, CO.

Other Notable Achievements

- **Cristy Pounders Singleton, Pharm.D., CPP:** Established a collaborative practice agreement with Carolina Mountain Emergency Medicine physician group as a clinical pharmacist practitioner at Mission Hospital, Asheville, NC.
- **Adam Landers, Pharm.D., BCPS, CPP:** Established a collaborative practice agreement with Carolina Mountain Emergency Medicine physician group as a clinical pharmacist practitioner at Mission Hospital, Asheville, NC.
- **Bethany Strickland Delk, Pharm.D., BCPS, CPP:** Established a collaborative practice agreement with Carolina Mountain Emergency Medicine physician group as a clinical pharmacist practitioner at Mission Hospital, Asheville, NC.

EMED PRN Committee Activities

- **CODE (the Collaborative Organization for Development of Emergency Medicine Pharmacists) Committee – Samantha Bastow, Pharm.D. (Chair):** Looking to expand your current emergency medicine pharmacy practice? Interested in sharing ideas to further pharmacy as a profession? Look no further!
We wanted to remind you of the exciting opportunity to join the EMED PRN CODE Program. The Collaborative Organization for Development of Emergency Medicine Pharmacists (CODE Program) encourages idea sharing and fosters professional growth by forming meaningful partnerships among emergency medicine pharmacists. Biannually, the program will match participants on the basis

of personally identified strengths and goals, as indicated on the registration form.

To participate, simply complete the Participant Bio found on the EMED PRN homepage under PRN Documents/CODE Program Documents/Bio for CODE Program Participant. All members are encouraged to join. We hope this will be a great tool for us to work together to advance our practice.

- **Educational Programming Committee – Mary Beth Shirk, Pharm.D., BCPS (Chair):**

The Programming Committee is developing the EMED PRN focus session for the 2013 ACCP Annual Meeting in Albuquerque, New Mexico. The title of the session will be “The Great Disappearing Act: Drug Shortages and Emergency Medicine.” This educational session will focus on the resurgence of medications used in emergency medicine and other acute care settings driven by ongoing drug shortages.

- **Media Committee – Craig Cocchio, Pharm.D., BCPS (Chair):**

The Media Committee is currently working on a spring newsletter that will feature two clinical topic reviews. The topics selected include a review of tranexamic acid and the CRASH-2 studies by two current emergency medicine PGY2 residents (Ruben Santiago, Pharm.D., and Nadia Awad, Pharm.D.) as well as a discussion surrounding the use of t-PA in patients taking dabigatran, rivaroxaban, or apixaban (Brittany L. Riley, Pharm.D., BCPS, and Brooke Bitner, Pharm.D., BCPS). The targeted release date for this newsletter is April 2013.

- **Travel Award Committee – Nicole M. Acquisto, Pharm.D., BCPS (Chair):**

The Travel Award Committee will give two awards this year to help support the costs of travel and attendance at the 2013 ACCP Annual Meeting. A call for abstracts and details of award requirements will be sent to EMED PRN members in August.

Endocrinology and Metabolism PRN

The Endocrine and Metabolism PRN is composed of members from a variety of practice settings. The PRN was formed to achieve the following goals and objectives: (1) provide an opportunity for pharmacists with an interest in endocrine and metabolism disorders to promote practice, research, and education in these areas; (2) provide a mechanism for members with similar interests to meet during ACCP meetings to network, problem solve, and discuss professional issues and opportunities; and (3) promote practice involvement; educational needs of health

care professionals, students, and patients; and research activities in the areas of endocrinology and metabolism that may be favorably affected by this ACCP PRN effort.

During the past 6 months, some notable member accomplishments are as follows.

Awards

- **Krystal L. Edwards:** Texas Tech University Health Sciences Center President’s Outstanding Clinician Award.
- **Brian K. Irons:** Texas Tech University Health Sciences Center 2012 President’s Excellence in Interprofessional Teamwork Award.
- **Nathan A. Painter:** Cardinal Health Generations Rx Champion Award from the California Pharmacists Association (CPhA). This award recognizes a pharmacist who has demonstrated excellence in community-based prescription drug abuse prevention.

Grants

- **Nicole R. Pinelli** (Principal Investigator). Intravenous Exenatide Infusion in Critically Ill Neurologic Injured Patients: A Proof of Concept Study. Funded, Bristol-Myers Squibb.

Publications

- **Jennifer Goldman-Levine**
 - **Goldman-Levine JD, Patel D, Schnee D.** Insulin degludec: a novel insulin analogue. *Ann Pharmacother* 2013;47:269-77.
 - Patel D, **Goldman-Levine JD.** Fidaxomicin (Dificid) for *Clostridium difficile*. *Am Fam Physician* 2013;87:211-2.
 - **Goldman-Levine JD, Dvorkin CL.** Patented medicine (complementary and alternative medicine for the treatment of type 2 diabetes). *Diabetes Self Manage* 2012;Sept/Oct:42-3.
- **Brian Irons**
 - **Irons B.** New pharmacotherapies for type 2 diabetes. In: Murphy J, Lee M, eds. *Pharmacotherapy Self-Assessment Program, 2013 Book 1. Cardiology and Endocrinology.* Lenexa, KS: American College of Clinical Pharmacy, 2013:5-25.
- **Nathan A. Painter**
 - **Painter NA, Morello CM, Singh RF, McBane SE.** An evidence-based and practical approach to using

Bydureon™ in patients with type 2 diabetes. J Am Board Fam Med 2013;26:203-10.

- **Devada Singh-Franco**
 - **Singh-Franco D**, Perez A, Wolowich W. Improvement in surrogate endpoints by a multidisciplinary team in a mobile clinic serving a low-income, immigrant minority population in South Florida. J Health Poor Underserved 2013;24:67-77.

Research Abstracts – Published in Academic Journals

- **Nicole R. Pinelli**
 - Ingemi I, Rech M, Fleming J, **Pinelli NR**, Moore C. 25-Hydroxy vitamin D status and the incidence of acute cellular rejection in kidney transplant recipients. J Am Soc Nephrol 2012;23:351A. Poster presented at: 2012 American Society of Nephrology Meeting; November 2012; San Diego, CA.

Presentations

- **Jennifer Goldman-Levine**
 - Evidence-based treatments for diabetic peripheral neuropathy. New Hampshire Pharmacists Association; March 2013 (1CE).
 - Barriers to insulin use and insulin pump use. Two-hour workshop presented to: pharmacists, physicians, nurses, clinical staff, and marketing staff. Becton Dickenson; January 2013; Billerica, MA.
 - T2DM 2012: Expert recommendations & evidence-based strategies for achieving optimal results; focus on the newer agents. Presented to: pharmacists and nurses at the Cardiovascular Clinical Update Continuing Education Conference on behalf of MSHP; November 2012; Westford, MA. (1CE)
 - Complications of diabetes: the management and impact on patients. Paper presented to pharmacists at: NHSHP 30th Annual Autumn Continuing Education Seminar; October 12, 2012; Concord, NH. (1.5CE)
 - More creative techniques to engage your audience in active learning. Two-hour workshop to pharmacists, presented at: ASHP Midyear Clinical Meeting; December 5, 2012; Las Vegas, NV. (2CE)
 - **Goldman-Levine JD**, Cook T. Active learning techniques for teaching in the pharmaceutical

sciences. Two-hour workshop to pharmacists, scientists, academics, and researchers, presented at: AAPS Annual Meeting; October 2012; Chicago, IL.

Other Notable Achievements

June Johnson served as item writer and on the Expert Review Panel for the BC-ADM examination (as a pharmacist member).

Marissa Quinones was recognized in the January 2013 ACCP Member Spotlight. She has been an active member of the Endocrine and Metabolism PRN for several years.

Resident Travel Scholarship

The Endocrine and Metabolism PRN Residency Travel Scholarship is intended to provide financial support for a resident-level member to attend the annual or spring ACCP meeting. The applicant must be a resident member (PGY1 or PGY2) in the ACCP Endocrine and Metabolism PRN. The applicant must provide a statement of why he or she is involved with the Endocrine and Metabolism PRN and describe how attending the meeting will assist in the applicant's career and/or residency goals. A current copy of the applicant's CV, highlighting professional organizations and community service, with one letter of recommendation are required for the complete application.

Congratulations to Dr. Sara Micale, an ambulatory care pharmacy practice resident at Albany College of Pharmacy and Health Sciences and The Endocrine Group, LLP, who will receive this year's ACCP Endocrine and Metabolism PRN Resident Scholarship. She will receive \$500 to attend the ACCP Updates in Therapeutics® Meeting in Reno, Nevada, in April.

Geriatrics PRN

The Geriatric PRN wishes to acknowledge its members' contributions to practice, scholarship, and teaching during the past 12 months.

Promotions

Virginia Skipper was promoted to Home-Based Primary Care Pharmacy Program Manager at the VA Puget Sound Healthcare System, Seattle, WA, in December 2012.

Awards

Allison B. Riendeau, 2012 AACP/Walmart Scholars Program Recipient, **Jena L. Ivey Burkhart**, Faculty Mentor

Grants/Research Funding

Jeff Hughes

- 2012 J.M. O'Hara Fund, PSWA. Correlation Between Vitamin D Levels and HbA1c and Inflammatory Markers in Aged Care Residents. \$10,000
- 2012 Alzheimer's Australia. Improving Pain Management Amongst Patients with Dementia. \$50,000
- 2012 J.M. O'Hara Fund, PSWA. Investigation of Relationship of Calcium Channel Blockers and Male Urinary and Prostatic Health, Using Linked Data. \$10,000

Jeannie Kim Lee

Title: Arizona Geriatric Education Center

Source: Department of Health and Human Services, Health Resources and Services Administration

Goal: To train health professionals throughout the state in the care of older adults

Role: Coinvestigator and member of interprofessional geriatric scholars; providing clinical pharmacy expertise and education related to pharmacology in aging, pharmacotherapy, and medication management and adherence

Amount: \$2,100,000

Date: July 2012 – Present

Publications

Matthew Cantrell

1. **Cantrell M**, Argo T, Haak L, Janney L. Neuropsychiatric adverse effects associated with varenicline: a case series. *Issues Ment Health Nurs* 2012;33:665-9.
2. **Cantrell M**, Bream-Rouwenhorst HR, Watts C, Oetting TA. Pathophysiology and pre-operative evaluation of patients at risk for intraoperative floppy iris syndrome (IFIS). In: Zaidi FH, ed. *Cataract Surgery*. Rijeka, Croatia: InTech, 2013:chap 1.

Jeff Hughes

1. Jiwa M, **Hughes JD**, O'Connor M, Tuffin P. Field testing a protocol to facilitate the involvement of pharmacists in community based palliative care. *Aust Pharm* 2012;31:72-7.
2. Jiwa M, Meng X, Sririam D, **Hughes JD**, Colagiuri S, Twigg S, Skinner T, Shaw T. The management of type 2 diabetes: a survey of Australian general practitioners. *Diabetes Res Clin Pract* 2012;95:326-32.
3. **Hughes J**, Coniglio N, Protuder N, Stamatis E. The

effect of proton pump inhibitors in increasing the risk of developing travellers' diarrhoea – a literature review. *Aust Pharm* 2012;31:416-8.

4. Omar M, Crowe A, Parsons RW, Eh H, Tay CY, **Hughes JD**. P-glycoprotein expression in *Helicobacter pylori* positive patients: the influence of MDR1 (C3435T) polymorphism. *J Dig Dis* 2012;13:414-20.
5. Thompson AJ, Peterson GM, Jackson SL, **Hughes JD**, Redmond K. Utilizing community pharmacy dispensing records to disclose errors in hospital admission drug charts. *Int J Clin Pharmacol Ther* 2012;50:639-46.
6. Jiwa M, **Hughes JD**, Sririam D. Piloting and validating an innovation to triage patients presenting with cough to community pharmacies in Western Australia. *Qual Prim Care* 2012;20:83-91.
7. Hoti K, **Hughes JD**, Sunderland VB. Medication supply to residential aged care facilities in Western Australia using a centralized medication chart to replace prescriptions. *BMC Geriatr* 2012;12:1-6.
8. Hoti K, **Hughes J**, Sunderland VB. Identifying the perceived training needs for Australian pharmacist prescribers. *Int J Pharm Pract*. 2013 Jan 10. [Epub ahead of print]

Jena L. Ivey Burkhart

Lauffenburger JC, Vu MB, **Ivey Burkhart JL**, Weinberger M, Roth MT. Design of a medication therapy management program for Medicare beneficiaries: qualitative findings from patients and physicians. *Am J Geriatr Pharmacother* 2012;10:129-38.

Carlos Rojas-Fernandez

1. **Rojas-Fernandez CH**, Mikhail M. Contemporary concepts in the pharmacotherapy of depression in older people [review]. *Can Pharm J* 2012;145:128-35.
2. **Rojas-Fernandez CH**, Cameron J. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations [narrative review]. *Ann Pharmacother* 2012;46:696-702.
3. **Rojas-Fernandez CH**, MacLaughlin EJ, Dore NL, Ebsary S. Assessing the potential adverse consequences of supplemental calcium on cardiovascular outcomes: should we change our approach to bone health [narrative review]? *Ann Pharmacother* 2012;46:549-57.

Jeannie Kim Lee

1. **Lee JK**, Mendoza DM, Mohler J, Lee EM. Geriatrics. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, et

al., eds. *Pharmacotherapy Principles & Practice*, 3rd ed. New York: McGraw-Hill, 2013:7-21.

2. Weiss B, **Lee JK**. Is your patient taking too many pills? Before you prescribe another drug, consider whether new symptoms might be caused by the medications the patient is already taking. *J Fam Pract* 2012;61:652-61.
3. **Lee JK**. Pharmacotherapy of depression in older adults. *Ariz Geriatr Soc J* 2012;17:31-2.
4. Huber M, **Lee JK**. Bisphosphonates, acid-suppressive therapy, and fracture risk in older adults. *Ariz Geriatr Soc J* 2012;17:12-3.
5. Tang D, Armstrong E, **Lee JK**. A cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. *Pharmacotherapy* 2012;32:515-26.
6. Warholak TL, Smith K, Legner D, Rupp MT, **Lee JK**. Features of electronic prescribing software: a pilot study to evaluate importance and satisfaction. *Ariz J Pharm* 2012;4:15-20.

Amy Tiemeier

1. Grice GR, Gattas NM, Sailors J, Murphy JA, **Tiemeier AM**, Hurd, P, Prosser T, Berry T, Duncan W. Health literacy: use of the four habits model to improve student pharmacists' communication. *Patient Educ Couns* 2013;90:23-8.
2. Cain J, Scott DR, Metzger A, **Tiemeier AM**. Social media use by pharmacy faculty: student friending, e-professionalism, and professional use. *Curr Pharm Teach Learn* 2013;5:2-8.
3. Vouri SM, **Tiemeier AM**. The ins and outs of pharmacy services at a Program of All-inclusive Care for the Elderly (PACE) organization. *Consult Pharm* 2012;27:803-7.

Other Notable Achievements

Mary Douzjian: Certified as BCPS.

Gregory J. Hughes: Assessment of medical resident drug information skills at an academic medical center. Paper presented at: Innovations in Drug Information Practice and Research session; ASHP Midyear Clinical Meeting; December 5, 2012; Las Vegas, NV.

Jeannie Kim Lee: Caring for older adults with disabilities. Media presentation at: UA BioMedical Communications, Interprofessional Education & Practice (IPEP) Disabilities Event; March 2012.

Jena L. Ivey Burkhart: Recertified for BCPS.

Deirdre P. Pierce: Certified as CGP.

Leslie Richard: Certified as CGP.

GI/Liver/Nutrition PRN

The GI/Liver/Nutrition PRN would like to acknowledge and congratulate the following members on their notable accomplishments.

Awards

April Smith received the Educator of the Year award from the fourth-year pharmacy student class at Creighton University School of Pharmacy and Health Professions.

Publications

1. **Singh-Franco D**, Perez A, Wolowich W. Improvement in surrogate endpoints by a multidisciplinary team in a mobile clinic serving a low-income, immigrant minority population in South Florida. *J Health Poor Underserved* 2013;24:67-77.
2. American College of Clinical Pharmacy (ACCP); Kirwin J, Canales AE, Bentley ML, Bungay K, Chan T, Dobson E, Holder RM, Johnson D, Lilliston A, **Mohammad RA**, Spinler SA. ACCP white paper: process indicators of quality pharmacist services in various types of transitions of care. *Pharmacotherapy* 2012;32:e338-47.
3. **Mohammad RA**, Regal R, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. *Ann Pharmacother* 2012;46:1559-63.

Other Notable Achievements

1. **Lynn Radonic Patton** was elected president of the Arizona Society for Parenteral and Enteral Nutrition.
2. **April Smith** was invited to speak at the ACCP 2012 Annual Meeting during the GI/Liver/Nutrition PRN session. The topic was "Medical Management of Chronic Disease in the Post-Bariatric Surgery Patient."
3. **April Smith** was invited to speak at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting. The topics were "The Role of the Pharmacist on the Bariatric Surgery Team" and "Drug Absorption Issues Post-Bariatric Surgery."
4. **April Smith** was invited to speak at the Alegant Health Bariatric Symposium. The topic was "Psychiatric Medication Use in the Bariatric Surgery Population."
5. **Juliana Chan** became a Board Certified Ambulatory Care Pharmacist (BCACP).

Hematology/Oncology PRN

Introduction

The Hematology/Oncology PRN facilitates the timely dissemination of information related to the clinical practice, research, and teaching of hematology and

oncology among its members and serves as a resource for hematology and oncology expertise to others. The PRN provides a forum for hematology/oncology pharmacists to network and collaborate on scientific, educational, and political issues affecting clinical practice, teaching, and research.

Promotions

JoEllen L. Hanigosky, Pharm.D.; Clinical Coordinator, Hematology/Oncology/Bone Marrow Transplant, Akron Children's Hospital, has been promoted to inaugural pharmacy research scholar for the children's oncology group.

Grants

Jeannine S. McCune, Pharm.D.; Professor, University of Washington, and Associate Member, Fred Hutchinson Cancer Research Center. Principal investigator on the following grant: Pharmacogenetics of Cyclophosphamide ADRs in Children. 1 R21 CA162059-01A2.

Publications

John Bossaer, Pharm.D., BCPS, BCOP: Assistant Professor, Gatton College of Pharmacy, East Tennessee State University:

1. **Bossaer JB**, Lewis PO. Antibiotic use in home health: a primer. *Home Health Care Manage Pract* 2012;24:50-5.
2. **Bossaer JB**, Odle BL. Probable etoposide interaction with *Echinacea*. *J Diet Suppl* 2012;9:90-5.
3. Chakraborty K, **Bossaer J**, Patel R, Krishnan K. Successful treatment of nilotinib-induced pleural effusion with prednisone. *J Oncol Pharm Pract*. [Published online ahead of print November 15, 2012]
4. **Bossaer JB**, Cluck D. Home health care of patients with neutropenic fever. *Home Health Care Manage Pract*. [Published online ahead of print February 27, 2013]
5. **Bossaer JB**, Gray JA, Miller SE, Enck G, Gaddipati VC, Enck RE. The use (and misuse) of "cognitive enhancers" by students at an academic health sciences center: the elephant in the room. *Acad Med*. Accepted for publication.
6. Abu-Shahin FI, **Bossaer JB**, Enck RE. Soft tissue calcification secondary to imatinib mesylate in a patient with gastrointestinal stromal tumor (GIST). *J Oncol Pharm Pract*. Accepted for publication.

Niesha Griffith, RPh, M.S., FASHP: Director of Pharmacy and Infusion Services at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University:

Frame JN, Jacobson JO, Vogel WH, **Griffith NL**, et al. Assessment of Risk-Evaluation and Mitigation Strategies in oncology: summary of the Oncology Risk Evaluation and Mitigation Strategies Workshop. *J Oncol Pract*. 2012 Oct 30. [Epub ahead of print]

Christy S. Harris, Pharm.D., BCPS, BCOP: Assistant Professor, Massachusetts College of Pharmacy and Health Sciences – Boston:

1. **Harris CS**, Wang D, Carulli A. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature. *J Oncol Pharm Pract*. [Published online ahead of print March 11, 2013]
2. Cirrone F, **Harris CS**. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. *Clin Ther* 2012;34:2039-50.

Pamala Jacobson, Pharm.D.: Associate Professor, Experimental and Clinical Pharmacology, College of Pharmacy, Minneapolis; Book: new edition published, **Jacobson**, Senior Editor:

1. Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, **Jacobson PA**, Kradjan WA, Williams BR, senior eds. *Applied Therapeutics: The Clinical Use of Drugs*, 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2013.
2. Thyagarajan B, Jackson S, Basu S, **Jacobson PA**, Gross M, Weisdorf D, Arora M. Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplantation. *Int J Immunogenet*. 2012 May 30. [Epub ahead of print]
3. Frymoyer A, Verotta D, **Jacobson P**, Long-Boyle J. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic hematopoietic cell transplantation: effect of pharmacogenetic factors. *Br J Clin Pharmacol* 2013;75:463-75.
4. Johnson LA, Tretyakova N, **Jacobson PA**. Obesity effects on cyclophosphamide-induced DNA damage in hematopoietic cell transplant recipients. *In Vivo* 2012;26:853-7.
5. Passey C,* Birnbaum A, Brundage R, Oetting W, Leduc R, Israni A, Guan W, Matas A, **Jacobson PA**. Validation of tacrolimus equation to predict troughs using genetic and clinical factors. *Pharmacogenomics* 2012;13:1141-7.
6. Kim H,* Long-Boyle J,* Rydholm N, Orchard PJ, Tolar J, Smith AR, **Jacobson P**, Brundage R. Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. *J Clin Pharmacol* 2012;52:1665-75. K: to here on second edit

7. Jensen K,* Johnson LA, **Jacobson PA**, Kachler S, Kirstein MN, Lamba J, Klotz KN. Cytotoxic purine nucleoside analogues bind to A(1), A(2A), and A(3) adenosine receptors. *Naunyn Schmiedebergs Arch Pharmacol* 2012;385:519-25.
8. Johnson LA, Malayappan B, Tretyakova N, Campbell C, MacMillan ML, Wagner JE, **Jacobson PA**. Formation of cyclophosphamide-specific DNA adducts in hematological diseases. *Pediatr Blood Cancer* 2012;58:708-14.

*Designates a trainee at time of research.

Tali M. Johnson, Pharm.D., BCOP: Senior Clinical Research Pharmacist, Pharmaceutical Management Branch, CTEP/DCTD/NCI/NIH:

Johnson TM, Boron MJ. Early access to investigational agents through the National Cancer Institute's Treatment Referral Center. *J Hematol Oncol Pharm* 2012;2:120-7.

Jeannine S. McCune, Pharm.D.: Professor, University of Washington, and Associate Member, Fred Hutchinson Cancer Research Center:

1. Li H, **McCune JS**, Salinger DH, Vicini P, Bemer MJ, Mager DE. Population pharmacokinetic model and limited sampling schedule for mycophenolic acid after IV mycophenolate mofetil administration in hematopoietic cell transplant recipients. *J Clin Pharmacol* 2012;52:1654-64.
2. **McCune JS**, Baker KS, Gamis A, Bemer MJ, Kelton-Rehkopf M, Barrett JS. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. *J Clin Pharmacol* 2013;53:264-75.
3. Chow EJ, Pihoker C, Friedman DL, Lee SJ, **McCune JS**, Wharton C, Roth CL, Baker KS. Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. 2013;60:621-6.
4. Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, **McCune JS**. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. *J Clin Pharmacol*. 2013 Feb 4:1-6. [Epub ahead of print]

Pamala A. Pawloski, Pharm.D.: Research Associate, HealthPartners Institute for Education and Research, Bloomington, MN:

1. **Pawloski PA**, Geiger AM, Haque R, Kamineni A, Fouayzi H, Ogarek J, Petersen HV, Bosco JLF, Thwin SS, Silliman RA, Field TS. Fracture risk in older, long-term survivors of early-stage breast cancer. *J Am Geriatr Soc*. Accepted for publication February 2013.

2. Cross D, Rahm AK, Kauffman TL, Webster J, Le AQ, Feigelson HS, Alexander G, Meier P, Onitilo A, **Pawloski PA**, Williams AE, Honda S, Daida YH, McCarty CA, Goddard KAB. Under-utilization of Lynch syndrome screening in a multisite study of colorectal cancer patients. *Genet Med*. Accepted for publication February 2013.
3. Webster J, Kauffman T, Feigelson HS, **Pawloski P**, Onitilo AA, Potosky AL, Cross D, Meier P, Mirabedi AS, Delate T, Daida Y, Williams A, Alexander GL, McCarty CA, Honda S, Kushi LH, Goddard KAB; on behalf of the CERGEN Study Team. *KRAS* testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. *Cancer Epidemiol Biomark Prev*. 2012 Nov 15. [Epub ahead of print]
4. Clough-Gorr KM, Thwin SS, Bosco JLF, Silliman RA, St. Charles M, Buist DSM, **Pawloski PA**, Quinn VP, Prout MN. Incident malignancies among older long-term breast cancer survivors and age-site-matched non-breast cancer comparisons over ten-years of follow-up. *Cancer*. 2012 Dec 26. [Epub ahead of print]
5. Dudek AZ, Kumar P, Thaw SSH, Cao Q, **Pawloski P**, Larson T. Phase II study of biweekly carboplatin, gemcitabine and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC. *Am J Clin Oncol*. 2012 Oct 29. [Epub ahead of print]

New ACCP Fellow

David Baribeault, B.S., FCCP, BCOP: Clinical Adviser, Pharmacy Optimization, McKesson Health Solutions, Salem, MA.

Other Notable Achievements

Niesha Griffith, RPh, M.S., FASHP: Director of Pharmacy and Infusion Services at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, and the incoming HOPA president.

Pamala A. Pawloski, Pharm.D.: Research Associate, HealthPartners Institute for Education and Research. Her research proposal, titled "Colony-Stimulating Factor Use Among Cancer Patients in the Managed Care Setting," was selected in February 2013 for the HMO Research Network Cancer Research (CRN) Scholars Program, a 26-month mentoring program aimed at using CRN resources for large-scale, multisite, population-based research. Eight investigator-initiated proposals were selected for this program.

Osama Abu Tabar, BSP Pharm, BCOP: Cancer care Pharmacist, Saudi Aramco Medical Services: Certified as BCOP.

Immunology/Transplantation PRN

The Immunology/Transplantation Practice and Research Network (PRN) has grown to almost 393 members. We encourage all members to get involved and to provide us with suggestions and comments to make our PRN even better.

Our PRN will be well represented at the American Transplant Congress 2013 Annual Meeting (the joint annual meeting of the American Society of Transplant Surgeons [ASTS] and the American Society of Transplantation [AST]), with many presentations involving PRN members (see below). Congratulations!

Promotions

Timothy Clifford was promoted from a clinical specialist to a clinical pharmacy coordinator – transplantation at UK HealthCare.

Christopher Ensor changed institutions and started a new appointment: Assistant Professor, Pharmacy and Therapeutics, at the University of Pittsburgh School of Pharmacy.

Tiffany Kaiser was promoted to an associate professor of medicine, Division of Digestive Disease, University of Cincinnati.

Jennifer Trofe-Clark was promoted to an adjunct associate professor of medicine in the Renal Electrolyte and Hypertension Division of the Perelman School of Medicine, University of Pennsylvania.

Gregory Smallwood was promoted to an associate professor of pharmacy practice, beginning July 1, 2013.

Grants

Kathleen M. Tornatore has two active grants:

1. The Influence of Diabetes on Myfortic (Enteric-Coated Mycophenolic Acid Sodium) Pharmacokinetics and Adverse Drug Effects in Stable African American and Caucasian Renal Transplant Recipients (CERL080AUS91T); Novartis-Investigator Initiative; Principal investigator; June 2011 – January 2013.
2. Pharmacodynamics and Pharmacokinetics of Immunosuppressive Agents; from the Empire Clinical Research Investigator Program (ECRIP) for training transplant physician fellows in clinical research; Program Mentor; Rocco Venuto, Principal investigator; August 2013 – September 2013.

Publications

We would like to congratulate the following PRN members on their publications during the past several months.

- **Descourouez JL**, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant *Enterococcus faecium* from renal transplant patients with infected urinary stents. *Antimicrob Agents Chemother* 2013;57:1518-20.
- Gabardi S, Millen P, Hurwitz S, **Martin ST**, Roberts KL, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as *Pneumocystis jiroveci* pneumonia prophylaxis following renal transplantation. *Clin Transplant* 2012;26:E184-90.
- Hammond SP, **Martin ST**, Roberts KL, Gabardi S, Fuhlbrigge AL, Camp PC, Goldberg H, Marty FM, Baden LR. Cytomegalovirus in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. *Transpl Infect Dis* 2012. [Epub ahead of print]
- Khanmoradi K, **Knorr JP**, Feysa EL, Parsikia A, Jawa P, Dinh DB, Campos S, Zaki RF, Ortiz JA. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients. *Exp Clin Transplant*. 2013 Feb 22. [Epub ahead of print]
- **Knorr JP**, Javed I, Sahni N, Cankurtaran CZ, Ortiz JA. Metronidazole-induced encephalopathy in a patient with end-stage liver disease. *Case Rep Hepatol* 2012;DOI:10.1155/2012/209258.
- Leeser DB, **Aull MJ**, Afaneh C, Dadhania D, Charlton M, **Walker JK**, Hartono C, Serur D, Del Pizzo JJ, Kapur S. Living donor kidney paired donation transplantation: experience as a founding member center of the National Kidney Registry. *Clin Transplant* 2012;26:E213-22.
- **Martin ST**, Torabi MJ, Gabardi S. Influenza in solid organ transplant recipients. *Ann Pharmacother* 2012;46:255-64.
- MacLaren R, **Krisl JC**, Cochrane RE, Mueller SW. A case-based approach to the practical application of dexmedetomidine in critically ill adults. *Pharmacotherapy* 2013;33:165-86. Muthukumar T, Afaneh C, Ding R, **Tsapepas D**, Lubetzky M, Jacobs S, Lee J, Sharma V, Lee J, Dadhania D, Hartono C, **McDermott J**, **Aull M**, Leeser D, Kapur S, Serur D, Suthanthiran M. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. *Transplantation* 2013;95:711-20.
- Shah S, **Tsapepas DS**, Kubin CJ, **Martin ST**, Mohan S, Ratner LE, Pereira M, Kapur S, Dadhania D,

- Walker-McDermott JK.** Risk factors associated with *Clostridium difficile* infection after kidney and pancreas transplantation. *Transplant Infect Dis*. In press.
- Tiwari R, Tsapepas DS, Powell JT, **Martin ST.** Enhancements in healthcare information technology systems: customizing vendor supplied clinical decision support for a high-risk patient population. *J Am Med Inform Assoc* 2012. [Epub ahead of print]
 - **Trofe-Clark J,** Lemonovich TL; the AST Infectious Diseases Community of Practice. Interactions between anti-infective agents and immunosuppressants in solid organ transplantation. *Am J Transplant* 2013;13:318-26.
 - **Trofe-Clark J,** Sparkes T, Gentile C, Van Deerline V, Sawinski D, Bloom RD. BK virus and genotype variance and discordant BK viremia PCR assay results [letter to the editor]. *Am J Transplant*. 2013 Feb .
 - **Vu D,** Tellez-Corrales E, Sakharkar P, Kissen MS, Shah T, Hutchinson I, Min DI. Genetic polymorphisms of NF- κ B and allograft survival after kidney transplantation in the Hispanic allograft recipients. *Transpl Immunol* 2013;28:18-23.
 - Shah T, **Vu D,** Corrales-Tellez E, Cicciarelli J, Hutchinson I, Naraghi R, Min DI. Effects of mycophenolic acid on highly sensitized patients awaiting kidney transplant. *Transpl Immunol* 2013;28:32-7.
 - **Vu D,** Sakharkar P, Tellez-Corrales E, Shah T, Hutchinson I, Min DI. Association of vitamin D binding protein polymorphism with long-term kidney allograft survival in Hispanic kidney transplant recipients. *Mol Biol Rep* 2013;40:933-9.
 - **Vu D,** Tellez-Corrales E, Shah T, Naraghi R, Hutchinson IV, Min D. Association between granzyme B and perforin I polymorphisms and allograft outcomes in Hispanic kidney transplant recipients. *Clin Transplant*. In press.
 - **Vu D,** Tellez-Corrales E, Shah T, Naraghi R, Hutchinson IV, Min D. Gene polymorphisms of *UGT1A8*, *UGT1A9* and *HNF-1 α* are associated with gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. *Mol Biol Rep*. In press.
 - Wolf M, **Descourouez JL,** Hager DR, Djamali A. Peripheral administration of antithymocyte globulins: a review of current literature. *Transplant Rev (Orlando)* 2013;27:17-20.
 - Staino C, Lewin JJ, Nesbit TW, Sullivan B, **Ensor CR.** Survey of transplant-related pharmacy services at large comprehensive transplant centers in the United States. *Prog Transplant* 2013;23:23-7.
 - **Ensor CR,** Doligalski CT. Proliferation signal inhibitor toxicities after thoracic transplantation. *Expert Opin Drug Metab Toxicol* 2013;9:63-77.
 - Cahoon WD, **Ensor CR,** Shullo MA. Alemtuzumab for cytolytic induction immunosuppression in cardiac transplantation. *Prog Transplant* 2012;22:344-50.
 - Kruer R, **Ensor CR.** Colloids in the intensive care unit. *Am J Health Syst Pharm* 2012;69:1635-42.
 - Hynicka LM, **Ensor CR.** Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. *Ann Pharmacother* 2012;46:558-66.
 - **Jacobson PA,** Schladt D, Israni A, Oetting WS, Lin Y, Leduc R, Guan W, Lamba V, Matas AJ; DeKAF Investigators. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. *Transplantation* 2012;93:624-31.
 - Passey C, Birnbaum A, Brundage R, Oetting W, Leduc R, Israni A, Guan W, Matas A, **Jacobson PA.** Validation of tacrolimus equation to predict troughs using genetic and clinical factors. *Pharmacogenomics* 2012;13:1141-7.
 - Abecassis M, Bridges ND, Clancy CJ, Dew MA, Eldadah B, Englesbe MJ, Flessner MF, Frank JC, Friedewald J, Gill J, Gries C, Halter JB, Hartmann EL, Hazzard WR, Horne FM, Hosenpud J, **Jacobson P,** Kasiske BL, Lake J, Loomba R, Malani PN, Moore TM, Murray A, Nguyen MH, Powe NR, Reese PP, Reynolds H, Samaniego MD, Schmader KE, Segev DL, Shah AS, Singer LG, Sosa JA, Stewart ZA, Tan JC, Williams WW, Zaas DW, High KP. Workshop Proceedings: Solid organ transplantation in older adults: current status and future research. Summarized the workshop held January 23–24, 2012. *Am J Transplant* 2012;12:2608-22.
 - **Jacobson PA,** Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A; DeKAF Investigators. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. *Am J Transplant* 2012;12:3326-36.
 - Oetting WS, Guan W, Schladt DP, Leduc RE, Jacobson PA, Matas AJ, Chinnakotla S, Schröppel B, Murphy BT, Israni AK. Donor polymorphisms of TLR4 associated with graft failure in liver transplant recipients. *Liver Transpl* 2012;18:1399-405.

- Walsh KA, Lewis DA, **Clifford TM**, Hundley JC, Angulo P, Davis GA. Risk factors for venous thromboembolism in patients with chronic liver disease. *Ann Pharmacother* 2013;47:333-9.
- Thompson ML, Flynn JD, **Clifford TM**. Pharmacotherapy of lung transplantation: an overview. *J Pharm Pract* 2013;26:5-13.
- **Schmidt N**, Alloway RR, Walsh RC, Sadaka B, Shields AR, Girnita AL, Hanseman DJ, Woodle ES. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. *Transplantation* 2012;94:352-61.
- Sadaka B, Alloway RR, Shields AR, **Schmidt NM**, Woodle ES. Proteasome inhibition for antibody-mediated rejection. *Semin Hematol* 2012;49:263-9.
- Kumar R, Pendyala P, Sudchada P, Venuto R, Gray V, Gundroo A, Attwood K, Wilding G, **Tornatore K**. Comparison of repeated measurement of clearance (CrCl) to estimated glomerular filtration rate (eGFR) in stable renal transplant recipients. *J Nephrol*. Published January 2013.
- **Tornatore KM**, Minderman H, Chiang S, O'Loughlin K, Attwood K, Venuto RC. P-glycoprotein function in peripheral blood mononuclear cells in renal transplant recipients: sex and race influences. Presented at: Annual Meeting of Society of Clinical Pharmacology & Therapeutics; March 7 and 9, 2013; Indianapolis, IN.
- Meaney CJ, Brazeau D, Venuto RC, Chang S, Gundroo A, Leca N, Morse SE, Consiglio J, Cooper LM, **Tornatore KM**. Sex and haplotype associations with adverse effects of calcineurin inhibitors post-transplant. Poster presented at: Annual Meeting of Society of Clinical Pharmacology & Therapeutics; March 8, 2013; Indianapolis, IN.
- **Tornatore KM**, Minderman H, O'Loughlin K, Attwood K, Venuto RC. Gender and race influences on P-glycoprotein function in peripheral blood mononuclear cells and relation to tacrolimus adverse effects post-transplant. Presented at: Annual Meeting of European Solid Organ Transplant/American Society of Transplantation; October 12, 2012; Nice, France.
- **Tornatore KM**, Minderman H, McGuire O, O'Loughlin K, Shan G, Wilding G, Venuto RC. Nuclear localization of nuclear factor of activated T-cells for tacrolimus immunosuppression post-transplantation. Presented at: Annual Meeting of European Solid Organ Transplant/American Society of Transplantation; October 12, 2012; Nice, France.

Books

Senior Editors: Brian K. Alldredge, Robin L. Corelli, Michael E. Ernst, B. Joseph Guglielmo, **Pamala A. Jacobson**, Wayne A. Kradjan, and Bradley R. Williams. *Applied Therapeutics: The Clinical Use of Drugs*, 10th ed. 2013. On bookshelves in summer 2013.

Other Notable Achievements

Knorr JP, Sjeime MT, Braitman L, Jawa P, Zaki RF, Ortiz JA. Concomitant use of proton pump inhibitors and mycophenolate mofetil is associated with an increased risk of rejection in kidney transplant recipients. Poster session presented at: American Society of Nephrology Kidney Week 2012; October 30 – November 4, 2012; San Diego, CA.

Jennifer K. McDermott (Walker). American Society of Transplantation, Hepatitis B Donor Consensus Conference; invited pharmacy COP representative.

Kathleen M. Tornatore is serving as an immunosuppressive clinical pharmacology fellowship mentor for Calvin Meaney from September 5, 2013, to September 5, 2014.

Tiffany Kaiser received **The Ohio State University College of Pharmacy Josephine Sitterle Failer Alumni Award**. The award recognizes an alumnus who has received a professional degree from the college of pharmacy within the past 10 years and has made an outstanding contribution(s) to community or professional service.

Accepted ATC 2013 Poster Presentations

- **Trofe-Clark J**, Sawinski D, Sparkes T, Goral S, Bleicher M, Bloom R. Single center experience with long-term prospective BK monitoring in renal transplantation.
- Stevens DR, **Trofe-Clark J**, Blumberg E, Wilck M, Weikert B, Goral S, Bleicher M, Sawinski D, Abt P, Levine M, Porrett P, Bloom RD. Increased risk of breakthrough infection among cytomegalovirus donor positive/recipient negative kidney transplant recipients receiving lower dose valganciclovir prophylaxis.
- Banff scoring in early and late acute cellular rejection predicts graft survival. Presenter: **Jill Krisl**, Transplant Pharmacy Fellow, University of Cincinnati.
- Phenotypic classification of acute rejection correlates with long-term graft survival. Presenter: **Jill Krisl**, Transplant Pharmacy Fellow, University of Cincinnati.
- A single center evaluation of intravenous immunoglobulin in renal transplantation. Presenter: **Marissa**

L. Mako, PGY2 Pharmacy Resident-Solid Organ Transplantation, University of Wisconsin Hospital and Clinics.

- **McDermott JK**, Lee JR, **Aull M**, Muthukumar T, Hartono C, Serur D, Lee J, Sharma V, Kim J, Watkins A, Kapur S, Suthanthiran M, Dadhania D. Adjunctive bortezomib therapy for treatment of antibody mediated rejection in kidney transplant recipients.
- Jawa P, **Knorr JP**, Torres E, Raja R, Bradauskaite G, Kung SC. Donor hepatitis C status does not impact outcomes in hepatitis C positive kidney transplant recipients. Poster session to be presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.
- **Crowther B**, Hall R, Arar M, Ranch D. BK polyoma virus infection and efficacy of leflunomide in pediatric renal transplant recipients. Poster session to be presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.
- **Kuten SA**, **Patel SR**, Knight RJ, Gaber LW, Gaber AO. Course of BK virus infection in renal transplant recipients treated with cidofovir (oral presentation).
- **DeVos JM**, Knight RJ, **Patel SJ**, Land G, Graviss E, Teeter L, Gaber AO. Independent risk factors for de novo DSA development through prospective monitoring (oral presentation).
- **Patel SJ**, **DeVos JM**, Knight RJ, Gaber AO. Are some “high-risk” renal transplant recipients higher risk than others?
- **Patel SJ**, Knight RJ, Moore LW, Lehnert AL, Agbetoba AA, **DeVos JM**, Gaber AO. Early experience with 3-month ciprofloxacin prophylaxis for BK infection in renal transplantation.
- **Patel SJ**, Knight RJ, **Lawrecki TM**, **Masters BM**, Tannous PY, Gaber AO. Comparison of creatinine reduction ratio on day 2 with 6-hour post-operative creatinine reduction in defining early renal allograft function.
- **Patel SJ**, **DeVos JM**, **Dawson KL**, Knight RJ, Gaber AO. Infectious complications after depleting or non-depleting antibody induction in kidney transplant recipients over 60 years of age.
- **Ejaz NS**, Alloway RR, Sadaka B, Shields AR, Abu Jawdeh A, Paterno F, Cardi M, Woodle ES. Proteasome inhibitor-related toxicities in a prospective trial of desensitization. Poster session to be

presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.

- Min D, Vu D, **Kawawet B**, Poulsen J, Hutchinson I, Naraghi R, Shah T. Effect of ciprofloxacin on BK virus infection after renal transplantation. Poster session to be presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.

Accepted ATC 2013 Oral Presentations

- **Descourouez J**, Hager D, Levenson G, Hofmann RM, Djamali A, Bellingham J, Odorico J, Sollinger H, Pirsch J. Incidence, risk factors and outcomes of BK viremia and nephropathy following kidney, simultaneous kidney-pancreas or pancreas after kidney transplant. Oral presentation session to be presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.
- **Mako ML**. Thymoglobulin is associated with a significant reduction in de novo donor-specific antibodies and antibody mediated rejection in moderately sensitized renal transplant recipients. Oral presentation session to be presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.
- **DeVos JM**, Knight RJ, Patel SJ, Land GA, Graviss E, Teeter L, Gaber AO. Identification of independent risk factors for de novo DSA development through prospective monitoring. Oral presentation session to be presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.
- **Jantz AS**, **Patel SJ**, Moore LW, Knight RJ, Gaber AO. Application of rejection reversal as defined by efficacy endpoints in present day renal transplantation.
- **Jantz AS**, **Patel SJ**, Moore LW, Gaber LW, Knight RJ, Gaber AO. Creatinine as a marker of rejection reversal in recipients with post-treatment biopsies.
- **Ejaz NS**, Shields AR, Alloway RR, Sadaka B, Girnita A, Mogilishetty G, Kremer J, Cardi M, Woodle ES. A prospective, randomized, pilot study of B-cell targeted induction therapy in sensitized kidney transplant recipients: final report. Oral presentation session to be presented at: 13th American Transplant Congress; May 18–22, 2013; Seattle, WA.
- **Wang U**, **Yang A**, **Dong M**, **Busque S**. Safety and effectiveness of valganciclovir for cytomegalovirus prophylaxis in solid organ transplant patients on hemodialysis.

Infectious Diseases PRN

Grants (limited to 3)

Melody Berg received part of a CDC grant to develop the Regional Tuberculosis Consultation and Education Center at Mayo Clinic and received funding to be the pharmacist faculty member on the multidisciplinary team.

Kerry LaPlante received a \$705,000 grant (as Principal Investigator) from Pfizer Pharmaceuticals (ASPIRE grant) titled "Addressing Educational and Coordination Barriers for Adult Pneumococcal Disease Prevention in Rhode Island." She also received a second (\$50,000) grant from Pfizer Pharmaceuticals (ASPIRE grant) titled "Burden of Pneumococcal Disease in a National Cohort of Adults 50 Years and Older: Focus on Incidence and Prevalence of Disease Comorbidities." Finally, she received a \$100,000 grant from Pfizer Pharmaceuticals (ASPIRE grant) titled "The Effects of Obesity on the Comparative Effectiveness of Linezolid and Vancomycin in Methicillin-Resistant *Staphylococcus aureus* Pneumonia."

Publications (limited to 3)

Dumond J, **Adams J**, Prince H, Kendrick R, Wang R, Jennings S, Malone S, White N, Sykes C, **Corbett A**, Patterson K, Forrest A, **Kashuba A**. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. *HIV Med*. 2013 Feb 24. [Epub ahead of print]

Adams JL, Sykes C, Menezes P, Prince HMA, Patterson KB, Fransen K, Crucitti T, De Baetselier I, Van Damme L,

Kashuba ADM. Tenofovir diphosphate and emtricitabine phosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? *J Acquir Immune Defic Syndr* 2013;62:260-6.

Adams JL, Greener B, **Kashuba ADM**. Pharmacology of HIV integrase inhibitors. *Curr Opin HIV AIDS* 2012;7:390-400.

Nicol MR, **Adams JL**, **Kashuba ADM**. HIV PrEP trials: the road to success. *Clin Invest*. 2013 March. [Epub ahead of print]

Shibata A, McMullen E, Pham A, Belshan MA, Sanford B, Zhao Y, Goede M, Date A, **Destache CJ**. Polymeric nanoparticles containing combination antiretroviral drugs for HIV-1 treatment. *AIDS Rev Hum Retrovir*. 2013 Jan 7. [Epub ahead of print]

Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, **Destache CJ**. Development and evaluation of a thermosensitive vaginal gel containing raltegravir + efavirenz loaded nanoparticles for HIV prophylaxis. *Antivir Res*. 2012. [Epub ahead of print]

Knaak E, Cavalieri SM, Elsasser GN, Gonitzke A, Preheim LC, **Destache CJ**. Does antibiotic de-escalation for nosocomial pneumonia impact intensive care unit length of stay? *Infect Dis Clin Pract* 2012.

Sussman R, **Farkas A**, Lee A, Evaluation of pharmacist managed vancomycin therapy compared to physician managed dosing in establishing timely and therapeutic vancomycin serum concentrations at a community hospital. Paper presented at: Annual Meeting of the American College of Clinical Pharmacy; October 21–24, 2012; Hollywood, FL.

Farkas A. Pharmacodynamic profiling of prolonged infusion of ertapenem in critically ill patients with early-onset ventilator-associated pneumonia through the use of a population pharmacokinetic model and Monte Carlo simulation. Accepted for presentation at: 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2013; Berlin, Germany.

Farkas A. Model-based optimization of daptomycin dosing during high-intensity renal replacement therapy. Accepted for presentation at: 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 27–30, 2013; Berlin, Germany.

Santayana E, **Grim SA**, Janda WM, Layden JE, Lee TA, Clark NM. Risk factors and outcomes associated with vancomycin-resistant *Enterococcus* (VRE) infections with reduced susceptibility to linezolid. *Diagn Microbiol Infect Dis* 2012;74:39-42.

Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, **Tam VH**. Assessment of antimicrobial combinations for KPC-producing *Klebsiella pneumoniae*. *J Infect Dis* 2013;207:786-93.

Rose L. Management of HIV/AIDS in Older Adults. *Omnicare Geriatric Pharmaceutical Care Guidelines*® [Internet]; Updated 2013 Jan.

Segarra-Newnham M, Church TJ. Pharmacotherapy for methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia. *Ann Pharmacother* 2012;46:1678-87.

Segarra-Newnham M, Coakley C. Salvage options for eradication of *Helicobacter pylori* during tetracycline backorder. *J Pharm Technol* 2012;28:187-92.

Other Notable Achievements

Mary Beth Brinkman, **Lindsey Childs**, **Tom Dilworth**, **Ifeanyi Onor**, and **Kyle SobECKi** became Board Certified Pharmacotherapy Specialists in December 2012.

Lindsey Childs was appointed to the ASHP New Practitioners Forum Executive Committee (June 2013 – May 2014).

Tom Dilworth and **Lucia Rose** received AAHIVP credentialing.

Andras Farkas became a member of the International Society of Anti-Infective Pharmacology's group for bedside ICU antibiotic dosing, a working group that focuses on developing software applications to facilitate antibiotic dosing for critically ill patients at the bedside.

Nephrology PRN

During its annual business meeting and networking forum (October 2012), the Nephrology PRN discussed plans for the PRN. Several students attended and participated in the discussion. Travel award winner Desiree Kosmisky, a pharmacy student from the University of Pittsburgh School of Pharmacy, provided an interesting presentation of a project titled "Student Pharmacist-Based Medication Reconciliation to Identify Drug Record Discrepancies and Medication-Related Problems in an Outpatient Hemodialysis Unit," which was followed by an active discussion session. The Nephrology PRN was well represented at the 2012 American Society of Nephrology Renal Week meeting, with several members involved with committees, providing invited presentations and poster presentations. The PRN will also be well represented at the spring 2013 National Kidney Foundation Meeting, with several members involved in symposium planning, as invited speakers, and in committees and poster presentations.

Grants/Research

Amy Barton Pai. Contract: A Phase 1, Single-Center, Open-Label, Single-Dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil in Adults Receiving Continuous Renal Replacement Therapy. Forest Research Institute.

Publications

- Hogan J, **Schwenk MH**, Radhakrishnan J. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? *Kidney Int* 2012;82:1256-60.
- Low CL.** Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters. *Am J Health Syst Pharm* 2013;70:131-6.
- Rifkin DE, Abdelmalek JA, Miracle CM, **Low C**, Barsotti R, Rios P, Stepnowsky C, Agha Z. Linking clinic and home: a randomized, controlled clinical effectiveness trial of real-time, wireless blood pressure monitoring for older patients with kidney disease and hypertension. *Blood Press Monit* 2013;18:8-15.
- Golightly LK**, Teitelbaum I, Kiser TH, Levin DA, Barber GR, Jones MA, Stolpman NM, Lundin KS. *Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys*. New York: Springer Science+Business Media, 2013:1-752. Available at www.springer.com/medicine/nephrology/book.
- Jin R, Cai L, Tan M, McHutchison JG, **Dowling TC**, Howell CD. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. *Am J Gastroenterol* 2012;107:1675-83.
- Jin R, Fossler MJ, McHutchison JG, Howell CD, **Dowling TC.** Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. *AAPS J* 2012;14:571-80.
- Connelly K, **Nguyen TV.** Human immunodeficiency virus-associated nephropathy: a case assessment. *J Nurse Pract* 2013;9:40-5.
- Editor – **Nguyen TV**, et al. NJPhA Student Practitioner Newsletter. Published by NJPhA. Available at www.njpharmacist.org. 2012 fall (October).
- Mateo-Carrasco H, Gálvez-Contreras MC, Fernández-Ginés FD, **Nguyen TV.** Elevated liver enzymes resulting from an interaction between raltegravir and panax ginseng: a case report and brief review. *Drug Metab Drug Interact* 2012;27:171-5.
- Mueller BA**, Scoville BA. Adding to the armamentarium: antibiotic dosing in extended dialysis. *Clin J Am Soc Nephrol* 2012;7:373-5.
- Eyler RF**, Klein KC, **Mueller BA.** The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous veno-venous hemodialysis. *J Pediatr Pharmacol Ther* 2012;17:173-6.
- Eyler RF**, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, **Mueller BA.** The Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically Ill Subjects Receiving CVVHD and/or ECMO. *Pharmacotherapy* 2012;32:1061-9.
- Foote E**, Szarek J, Arscott K, Brady J, Clarke V, Easton D, Farrell M, Goss S, Walline V, Waters S. A Large Scale, Collaborative Care Summit to Promote Interprofessional Learning: Ischemic Stroke. *MedEdPORTAL* 2013. Available at www.mededportal.org/publication/9306.

- Butterfield JM, **Mueller BA**, Patel N, **Cardone KE**, **Grabe DW**, Salama NN, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. *Antimicrob Agents Chemother* 2013;57:864-72.
- **Scoville BA**, **Mueller BA**. Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy. *Am J Kidney Dis*. 2012 Nov 2. [Epub ahead of print]
- **Scoville BA**, Heung M, **Mueller BA**. Hemofiltration circuit use beyond 72 hours in pediatric continuous renal replacement therapy. *Int J Artif Organs* 2012;35:1025.
- **Vilay AM**, **Mueller BA**. Intradialytic oral nutritional supplements improve quality of life [letter]. *Am J Kidney Dis* 2013;61:349.
- **Mueller BA**, Jasiak KD, Thiel SR, Stevenson JM, **Vilay AM**, **Scoville BA**, **Churchwell MD**, Pasko DA, Perkins N. Vibration enhances clearance of solutes with varying molecular weights during in vitro hemodialysis. *ASAIO J* 2013;59:140-4.
- **El Nekidy WS**, El-Masri MM, Umstead GS, Dehoorne-Smith M. Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study. *Can J Hosp Pharm* 2012;65:436-42.
- Yaseen O, **El Nekidy WS**, Ibrahim AR, Jasey BB, Guignard M, Kadri A. Cyclic pseudoperitonitis secondary to endometriosis in a peritoneal dialysis patient. *Perit Dial Int* 2012;32:662-4.
- Yaseen O, El-Masri MM, **El Nekidy WS**, Soong D, Ibrahim M, Speirs JW, Kadri A. Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: the ALTE-DOSE study. *Hemodial Int*. 2012 Nov 26. [Epub ahead of print]
- **Dowling TC**, Rodriguez de Bittner M, **Perez Z**, Briglia A, Peralta L. Evaluation of drug metabolism in Hispanic Americans with type 2 diabetes. *J Diabetes Res Clin Metab* 2012 (doi: [dx.doi.org/10.7243/2050-0866-1-22](https://doi.org/10.7243/2050-0866-1-22)).
- **Pai AB**, Patel H, Prokopienko A, Gertzberg N, Alsaffar H, Neumann P, Punjabi A, Johnson A. Lipoteichoic acid from *Staphylococcus aureus* induces lung endothelial cell barrier dysfunction: role of reactive oxygen and nitrogen species. *PLoS One* 2012;7. [Epub ahead of print]
- Asif A, Carrillo R, Garisto JD, Monrroy M, Khan RA, Castro H, Merrill D, Ali AS, **Pai AB**, Waldman J, Salman L. Prevalence of chronic kidney disease in patients undergoing cardiac rhythm device removal. *Semin Dial*. 2012 Jul 11.
- Conner TA, McQuade CR, Olp J, **Pai AB**. Effect of intravenous vitamin C on reactive oxygen species generation, cytokine activation and oxidative stress in hemodialysis (HD) patients receiving intravenous iron sucrose (IS). *Biometals*. 2012 Jun 17.
- **Pai AB**, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease: or another dark cloud? *J Blood Med* 2012;3:77-85.
- Kubotera N, Prokopienko A, Garba AO, **Pai AB**. Endotoxin binding by sevelamer: potential impact on nutritional status. *Int J Nephrol*. Accepted for publication.
- **Richardson MM**, **Nolin TD**. A decade after the KDOQI CKD guidelines: impact on medication safety. *Am J Kidney Dis* 2012;60:713-5.
- **Cardone KE**, **Grabe DW**, Kulawy RW, Daoui R, Roglieri J, Meola S, Drusano GL, Lodise TP. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. *Antimicrob Agents Chemother* 2012;56:725-30.
- **Vilay AM**, Wong CS, Schrader RM, Mercier RC, Seifert SA. Indicators for serious kidney complications associated with toxic exposures: an analysis of the National Poison Data System. *Clin Toxicol (Phila)* 2013;51:96-105.
- **Churchwell MD**. Use of an in vitro model of renal replacement therapy systems to estimate extracorporeal drug removal. *J Clin Pharmacol* 2012;52(1 suppl):35S-44S.
- Samtani MN, Vaccaro N, Cirillo I, **Matzke GR**, Redman R, Nandy P. Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. *ISRN Pharmacol* 2012;2012:782656.
- American College of Clinical Pharmacy; Kirwin J, Canales AE, **Bentley ML**, Bungay K, Chan T, Dobson E, Holder RM, Johnson D, Lilliston A, Mohammad RA, Spinler SA. Process indicators of quality clinical pharmacy services during transitions of care. *Pharmacotherapy* 2012;32:e338-47.

BCPS Certification 2012

Ifeanyi Onor, Pharm.D., B.S., BCPS; clinical assistant professor and adult medicine clinical pharmacist; College of Pharmacy – Division of Clinical and Administrative Sciences; Xavier University of Louisiana

BCAP Certification 2012

Wasim S. El Nekidy, Pharm.D., BPharm, BCPS, BCACP, Clinical Pharmacy Specialist – Department of Nephrology, Hotel-Dieu Grace Hospital, Windsor, Ontario, Canada

Commission for Certification in Geriatric Pharmacy (CCGP)

Leslie Richard, Pharm.D., CGP, Cary, North Carolina

Symposium Presentations

American Society of Nephrology Annual Meeting

Amy Barton Pai. Role of pharmaceutical care on drug use and hospitalizations in ESRD patients. Paper presented at: American Society of Nephrology, Renal Week; November 2, 2012; San Diego, CA.

Michael Schwenk. Update: Treatment of Severe Lupus Nephritis Annual Regional Symposium on Chronic Kidney Disease. Featuring: CKD: The Cardiac-Kidney-Diabetes Connection. The National Kidney Foundation Serving Greater New York.

Pain and Palliative Care PRN

The Pain and Palliative Care PRN members continue to receive recognition for their accomplishments in publications, promotions, and other areas of achievement.

Awards

- **Alvarez NA**. Jack R. Cole, Ph.D, Distinguished Alumnus Award, The University of Arizona College of Pharmacy, 2012.
- **Alvarez NA**. Stellar Award – Clinical Development and Medical Science Department, Endo Health Solutions, Fourth quarter 2012.
- **Alvarez NA**. Leadership Attribute Award – Collaboration, Endo Health Solutions, Fourth quarter 2012.
- **McPherson ML**. Presidential Citation; Hospice and Palliative Care Nurses Association; February 2013.
- **McPherson ML**. University of Maryland Baltimore Founder's Week; Campus Teacher of the Year; October 2012.

Grants

- Department of Health and Mental Hygiene, State of Maryland, 2013. "Controlled Dangerous Substance Emergency Preparedness Plan." \$600,970; Walker K, **McPherson ML**, Co-Principal Investigators.
- NIH Pain Consortium: "Center of Excellence in Pain Education (CoEPE University of Maryland)." \$325,000; **McPherson ML**, Gordon S, Co-Principal Investigators.

Publications

- Sasu-Tenkoramaa J, **Fudin J**. Neuropathy in the cancer patient: causes and cures. *Pract Pain Manage* 2013;13:53-67.
- Kubotera N, **Fudin J**. Pain management for pharmacists – concepts and definitions. CE program of the University of Connecticut School of Pharmacy and Drug Topics. *Drug Top* 2013;April:52-61. In print.
- **Fudin J**, Fontenelle DV, Payne A. Rifampin reduces oral morphine absorption; a case of transdermal buprenorphine selection based on morphine pharmacokinetics. *J Pain Palliat Care Pharmacother* 2012;26:362-7.
- **Fudin J**. Commentary. PROMPT Challenges PROP's Petition. October 2012. *Pract Pain Manage* 2012;12:12-4.
- Haroutiunian S, **McNicol ED**, Lipman AG. Methadone for chronic non-cancer pain in adults. *Cochrane Database Syst Rev* 2012;11:CD008025.
- Liu J, Wang LN, **McNicol ED**. Pharmacological treatment for pain in Guillain-Barré syndrome [protocol]. *Cochrane Database Syst Rev* 2012;7:CD009950.
- **McPherson ML**. Opioid therapy for cancer pain. In: Tracey I, ed. *Pain 2012 Refresher Courses, 14th World Congress on Pain: International Association for the Study of Pain*. Seattle: IASP Press, 2012.
- **McPherson ML**, Kim M, Walker KA. 50 practical medication tips at end of life. *J Support Oncol* 2012;10:222-9.
- Sera LC, **McPherson ML**. Pharmacokinetics and pharmacodynamics changes associated with aging and implications for drug therapy. *Clin Geriatr Med* 2012;28:273-86.

Other Notable Achievements

- **Alvarez NA**. Installed as Trustee-at-Large – American Pharmacists Association – Second term.

- **Alvarez NA.** Established an APhA Academy of Student Pharmacists scholarship through the APhA Foundation – First awarded 2013.
- **Alvarez NA.** Leadership Weekend – California Pharmacists Association – Programming Codirector/Presenter, November 2012.
- **Fudin J.** Established new PGY2 Pain Residency Program at Stratton VA in Albany, NY (Candidate Status).
- **Fudin J.** Selected as ACCP National Mentor for residents, fellows, and graduate students.
- **Fudin J.** Founder of PROMPT (Professionals for Rational Opioid Monitoring and Pharmacotherapy).
- **McNicol ED.** Developed “blended learning” model for master’s degree in pain research, education and policy: publichealth.tufts.edu/Academics/MS-Pain-Research-Education-and-Policy/Programs-of-Study/MS-Pain-Research-Education-and-Policy.

Pediatrics PRN

Chair: Hanna Phan, Pharm.D., BCPS
 Immediate Past Chair: Kelly Bobo, Pharm.D., BCPS
 Chair-Elect: Barnabas John, Pharm.D., BPCS
 Secretary: Audrey Kennedy, Pharm.D., BCPS

The Pediatrics PRN is pleased to report the activities of its committees and to recognize the following accomplishments of its members.

Recent PRN Activity

Collaboration Committee (Chair: Joseph LaRochelle) – The efforts of the committee (which was led by Richard Parrish for this initial manuscript) have resulted in a dual publication in *Pharmacotherapy* and *Journal of Pediatric Pharmacology and Therapeutics* (see listing below). The collaboration committee has been hard at work designing a second paper that will focus on the clinical specialist’s role in the care of pediatric patients. This 18-person team has divided the main sections of the paper and is in the process of writing them. We have designed in the plan an editorial phase, which will include people with expertise in editing. After the editing phase, we will add the final touches to the paper and prepare for the final version. We have included an internal peer-review process that will provide comments to be addressed in the paper before submission to the journal.

Education Committee (Chair: Kelly Bobo) – The Education Committee continues to work on developing and submitting session proposals for the ACCP Annual Meeting each year.

Nominations Committee (Chair: Tracy Hagemann) – Continuing to encourage membership nominations for recognition within ACCP and candidates for office starting fall 2013. This year, we will be electing a new chair-elect (2-year term) and secretary (2-year term).

Student and Resident Committee (Chair: Chasity Shelton) – This is a new committee formed as part of the initiative to increase student and resident interest in pediatrics and participation in the Pediatrics PRN. Programs are currently being developed to provide mentorship and networking opportunities for students and residents.

Travel Award Committee (Chair: Hanna Phan) – Two awards will be available for application for 2013. These awards are for resident and student pediatric PRN members who are presenting (e.g., poster) at the ACCP Annual Meeting. Recipients of the award will be recognized at the annual PRN business meeting and will present their projects to those in attendance.

Promotions

Varsha Bhatt-Mehta was promoted to clinical professor of pharmacy, Department of Clinical Sciences, College of Pharmacy, University of Michigan.

Bernard Lee was promoted to pediatric clinical pharmacy manager at University of North Carolina Hospitals.

Grants

Deborah Raithe received the Pediatric Pharmacy Advocacy Group (PPAG) Neonatal Pharmacy Resident Small Research Grant for the project titled, “Neonatal Indomethacin for Prevention of Intraventricular Hemorrhage: A Study of Plasma Concentrations, Pharmacogenomic Factors, and Outcomes.”

Rebecca Chhim received one of the 2012–2013 American Association of Colleges of Pharmacy (AACP) New Investigator Awards for the project titled “Ethanol Dose Escalation Safety Study in Neonates and Infants.”

Awards

Milap Nahata was named a recipient of the 2013 recipient of the Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics from the Pediatric Pharmacy Advocacy Group. He will deliver the Yaffe Award Lecture during the 22nd Annual PPAG Meeting and 2013 Pediatric Pharmacy Conference on May 3, 2013.

Robert Kuhn was named the Kentucky Hospital Association Professor, an endowed professorship supported by the Kentucky Hospital Association.

Publications

- **Bhatt-Mehta V, Buck ML, Chung AM, Farrington EA, Hagemann TM, Hoff DS, La Rochelle JM, Pettit RS, Phan H, Potts AL, Smith KP, Parrish RH II.** Recommendations for Meeting the Pediatric Patient's Need for a Clinical Pharmacist: A Joint Opinion of the Pediatrics Practice and Research Network of the American College of Clinical Pharmacy and the Pediatric Pharmacy Advocacy Group.
 - J Pediatr Pharmacol Ther 2012;17:281-91.
 - Pharmacotherapy 2013;33:243-51.
- *Pediatric Pharmacotherapy*. Lenexa, KS: American College of Clinical Pharmacy, 2012. ISBN: 978-1-932658-89-7.
 - Editorial board: **Sandra Benavides, Milap C. Nahata, Michael Chicella, Michelle Condren, Lea S. Eiland, Tracy M. Hagemann, Jennifer Le, Kalen Manasco, Brady S. Moffett, Heather L. VandenBussche**
 - Contributing authors: Susan M. Abdel-Rahman, **Sandra Benavides, Varsha Bhatt-Mehta**, Jacob T. Brown, **Michael Chicella**, Joshua Caballero, Jennifer W. Chow, **Michelle Condren, Catherine M. Crill**, Kimberley Le Dinh, **Lea S. Eiland**, Tiffany-Jade M. Kreys, **Tracy M. Hagemann**, Kristin C. Klein, **Robert J. Kuhn, Mark Haase**, Cherry W. Jackson, **Weng Man Lam**, Jennifer Le, Raymond A. Lorenz, **Lisa Lubsch, Kalen Manasco, Erin J. McDade, Jaime Miller**, Brady S. Moffett, **Milap C. Nahata, Johanna L. Norman**, Vinita B. Pai, **Hanna Phan, Christina C. Piro**, Amy L. Potts, Jose A. Rey, Juan Carlos Rodriguez, Jason B. Sauberan, Christopher A. Thomas, **Heather L. VandenBussche**, Jeffrey L. Wagner, **Mary A. Worthington, Grace Lee**, Stephanie D. Natale, **Teresa V. Lewis**, Heidi Trinkman, Alix A. Dabb, M. Brooke Bernhardt, **Peter N. Johnson**
- Polischuk E, Vetterly CG, **Crowley KL**, et al. Implementation of a standardized process for ordering and dispensing of high-alert emergency medication infusions. J Pediatr Pharmacol Ther 2012;17:166-72.
- **Hiteshew KJ**, Franz T, Lamberjack K, Chen AMH. Don't leave without them: dispensing asthma medications to pediatric patients upon discharge is associated with decreased hospital readmissions. Innov Pharm 2012;3:Article 2.
- **LaRochelle JM**, Ghaly M, Creel AM. Clinical pharmacy faculty interventions in a pediatric intensive care unit: an eight-month review. J Pediatr Pharmacol Ther 2012;17:263-9.
- Manji A, Beyene J, **Dupuis LL**, Phillips R, Lehrnbecher T, Sung L. Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective and safe in children – a systematic review of prospective trials. Support Care Cancer 2012;20:1135-45.
- Manji A, Lehrnbecher T, **Dupuis LL**, Beyene J, Sung L. A meta-analysis of anti-pseudomonal penicillins and cephalosporins in pediatric patients with febrile neutropenia. Pediatr Infect Dis J 2012;31:353-9.
- Sung L, Manji A, Beyene J, **Dupuis LL**, Alexander S, Phillips R, Lehrnbecher T. Fluoroquinolones in children with fever and neutropenia. Pediatr Infect Dis J 2012;31:431-5.
- Manji A, Lehrnbecher T, **Dupuis LL**, Beyene J, Sung L. A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer 2012;20:2295-304.
- **Dupuis LL**, Ethier MC, Tomlinson D, Hesser T, Sung L. A systematic review of symptom assessment scales in children with cancer. BMC Cancer 2012;12:430.
- Schechter-Finkelstein T, Avila L, Frangoul H, Domm J, **Dupuis LL**, Naitani R, Pollock-Barziv S, Roifman C, Gassas A, Doyle J. The effect of acute graft versus host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children. Leuk Lymphoma 2013;54:105-9.
- Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, Hakim H, Santolaya M, Castagnola E, Davis BL, **Dupuis LL**, Gibson F, Groll AH, Gaur A, Gupta A, Kebudi R, Petrilli A, Steinbach WJ, Villarroel M, Zaoutis T, Sung L. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem cell transplantation. J Clin Oncol 2012;30:4427-38.
- **Dupuis LL**, Seto W, Teuffel O, Gibson P, Schultz K, Doyle J, Gassas A, Egeler RM, Sung L, Schechter T. Prediction of area under the cyclosporine concentration vs time curve in children undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2013;19:418-23.

- **Dupuis LL**, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, O'Shaughnessy E, Sung L. Guideline for the Prevention of Acute Nausea and Vomiting Due to Antineoplastic Medication in Pediatric Cancer Patients. Pediatric Oncology Group of Ontario; August 2012. Available at www.pogo.ca/healthcare/practiceguidelines/acuteainvguideline/.
- **Gargas A**. Neonatal and pediatric parenteral nutrition. AACN Adv Crit Care 2012;23:451-64.
- Dembinski K, **Gargas AE**, Dabrow S, Rodriguez L. Three distinct cases of copper deficiency in hospitalized pediatric patients. Clin Pediatr (Phila) 2012;51:759-62.
- Walker MC, Lam WM, **Manasco KB**. Review of continuous and extended infusions of beta-lactam antibiotics in the pediatric population. Ann Pharmacother 2012;46:1537-46.
- **Manasco KB**, Bradley AM, Gomez TA. Survey of learning opportunities in academia for pharmacy residents. Am J Health Syst Pharm 2012;69:1410-4.
- Sullins AK, Richard AA, **Manasco KB**, Phillips MS, Gomez TA. Which comes first, CPOE or eMAR? A retrospective analysis of health information technology implementation. Hosp Pharm 2012;47:1-8.
- Patanwala AE, Christich AC, Jasiak KD, Edwards CJ, **Phan H**, Snyder EM. Age-related Differences in Propofol Dosing for Procedural Sedation in the Emergency Department. J Emerg Med. 2013 Jan 16. [Epub ahead of print]
- **Phan H**, Porter K, Nahata M. Prescribing trends for medications in the treatment of adolescents and young adults with type 2 diabetes mellitus. J Manage Care Pharm 2012;18:607-14.
- Jasiak KD, **Phan H**, Christich AC, Edwards CJ, Skrepnek GH, Patanwala AE. Induction dose of propofol for pediatric patients undergoing procedural sedation in the emergency department. Pediatr Emerg Care 2012;28:440-2.
- Whittington Goldstone L, Kennedy AK, Clark JS, **Phan H**. Developing and evaluating clinical pharmacy services. In: Chisholm-Burns MA, Vaillancourt AM, Shepherd M, eds. Pharmacy Management, Leadership, Marketing, and Finance, 2nd ed. Burlington, MA: Jones & Bartlett, 2012:199-215.
- **Chhim RF, Shelton CM**, Christensen ML. Recent new drug approvals – part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther 2013;18:14-38.

- **Shelton CM, Chhim RF**, Christensen ML. Recent new drug approvals – part 1: drugs with pediatric indications. J Pediatr Pharmacol Ther 2012;17:329-39.
- Karimi Khaledi M, Suda KJ, **Shelton CM**. Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. Int J Clin Pharm 2012;34:822-4.
- Hicks JK, **Shelton CM**, Sahni JK, Christensen ML. A retrospective evaluation of enoxaparin dosing in patients 48 weeks postmenstrual age or younger located in a neonatal intensive care unit. Ann Pharmacother 2012;46:943-51.

Other Notable Achievements

A Pediatric Special Interest Group within the American Association of Colleges of Pharmacy was approved and formed. **Kalen B. Porter (Chair)**, **Tracey Hagemann (Chair-Elect)**, and **Hanna Phan (Secretary)** will serve in office starting in the summer of 2013.

Pharmaceutical Industry PRN

Promotion

Rick Barbarash, Pharm.D., FCCP, AstraZeneca, LP, Medical Affairs and Strategic Development. Promoted from senior regional scientific manager to executive regional scientific manager

Activities

The Industry PRN surveyed the members to assess whether there was a need to change the name of the PRN.

Because the pharmaceutical industry has evolved so much in recent years, the officers are exploring a member survey to help describe the vast array of roles and responsibilities of pharmacists within various functional areas of the industry.

Pharmacokinetics/Pharmacodynamics/Pharmacogenetics PRN

The PK/PD/PD PRN has been busy organizing a focus session for the upcoming ACCP Annual Meeting in October 2013. We look forward to an exciting session on applications of pharmacogenomics in clinical practice.

Publications

Formea CM, Nicholson WT, McCullough KB, Berg KD, Berg ML, Cunningham JL, Merten JA, Ou NN, Stollings JL. Development and evaluation of a pharmacogenomics

educational program for pharmacists. *Am J Pharm Educ* 2013;77:Article 9.

Murphy JE, Lee M, eds. *Cardiology/endocrinology. Pharmacotherapy Self-Assessment Program*, 8th ed. Lenexa, KS: American College of Clinical Pharmacy, 2013.

Women's Health PRN

The Women's Health PRN members continue to receive recognition for their accomplishments in publications, promotions, and other areas of achievement.

Publications

- **Forinash AB**, Yancey AM. Osteoporosis. In: Murphy J, Lee M, eds. *Pharmacotherapy Self-Assessment Program*, 2013 Book 1. *Cardiology and Endocrinology*. Lenexa, KS: American College of Clinical Pharmacy, 2013:51-77.
- **Forinash AB**, Yancey AM, **Barnes KN**, Myles T. The use of galactogogues in the breastfeeding mother. *Ann Pharmacother* 2012;46:1392-404.
- Painter N, Morello C, Singh R, **McBane S**. An evidence-based and practical approach to using Bydureon in patients with type 2 diabetes. *J Am Board Fam Med* 2013;26:203-10.
- **McBane S**. Tobacco cessation strategies. In: Dong B, Elliott D, eds. *Ambulatory Care Self-Assessment Program*, 2013 Book 1. *Pulmonary and Preventive Care*. Lenexa, KS: American College of Clinical Pharmacy, 2013:104-18.
- **McClendon KS**. Phentermine/topiramate ER (Qsymia): second new obesity medication approved in 2012 [update]. In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. *Pharmacotherapy: A Pathophysiologic Approach*, 8th ed. New York: McGraw-Hill, 2012. Available at www.accesspharmacy.com/updatesContent.aspx. Accessed December 3, 2012.
- **McClendon KS**. Lorcaserin approved for treatment of obesity [update]. In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. *Pharmacotherapy: A Pathophysiologic Approach*, 8th ed. New York: McGraw-Hill, 2012. Available at www.accesspharmacy.com/updatesContent.aspx. Accessed October 19, 2012.
- Dennis A, Blanchard K, Córdova D, Wahlin B, Clark J, Edlund K, **McIntosh J**, Tsikitas L. What happens to women who fall through the cracks of health care

reform? Lessons from Massachusetts. *J Health Polit Policy Law*. 2012 Dec 21.

- **Rafie S, McIntosh J, Gardner DK, Gawronski K, Karaoui LR, Koepf ER, Lehman KJ, McBane S, Patel-Shori NM**. Over-the-counter access to emergency contraception without age restriction: an opinion of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy. *Pharmacotherapy* 2013;33(5). [Epub ahead of print]

Other Notable Achievements

Diane Goodwin and **Sally Rafie** are now Board Certified Pharmacotherapy Specialists.

Karen Gunning is 2013 Chair of BPS Pharmacotherapy Specialty Council.

Christina Madison is 2013 president* of Nevada Public Health Association (term: October 2012 – October 2013).

*One of two pharmacists in the country to hold this position in a public health association.

Katie McLendon received the Mississippi Board of Trustees of State Institutions of Higher Learning award as the University of Mississippi Medical Center's 2013 Diversity Educator of the Year.

STUDENT INITIATIVES UPDATE

Student Member Demographics

We thank the many PRN members and liaisons who have encouraged students to consider professional membership in ACCP. Your efforts in reaching out to students have considerably helped expand opportunities for students within the organization. During the past 4 years, the number of ACCP student members has more than tripled, reaching 2000 members as of March 2013.



2013 ACCP Clinical Pharmacy Challenge Registration Now Open

Team registration is now available online. Please note that a current faculty member at the respective institution must initiate all team registrations. Students interested in forming a team should contact their ACCP [faculty liaison](#). All team registrations must be completed by the deadline compete in up to four online rounds, with the top eight teams advancing to the live quarterfinal competition at the 2013 ACCP Annual Meeting in Albuquerque, New Mexico, this October. Click [here](#) to view a detailed schedule of the 2013 competition.

The ACCP Clinical Pharmacy Challenge is a team-based competition. Teams of three students will compete against teams from other schools and colleges of pharmacy in a “quiz bowl”-type format. Only one team per institution can enter the competition. Institutions with branch campuses, distance satellites, and/or several interested teams are encouraged to hold a local competition. ACCP will provide a written examination that can be used by institutions as a basis for their local competition, if they so desire.

The local competition examination is now available and may be requested by the ACCP Faculty Liaison or the registering faculty member by e-mail. Please address your e-mail request to Michelle Kucera, Pharm.D., BCPS, at mkucera@accp.com. For more information on the local competition, click [here](#). Each round of the ACCP Clinical Pharmacy Challenge will consist of questions offered in the three distinct segments indicated in the bulleted items below. An expert panel of clinical pharmacy practitioners and educators has developed and reviewed the item content used in each segment.

- Trivia/Lightning
- Clinical Case
- Jeopardy-style

Each team advancing to the quarterfinal round held at the ACCP Annual Meeting will receive three complimentary student full meeting registrations. Each team member will receive an ACCP gift certificate for \$125 and a certificate of recognition. In addition, semifinal teams not advancing to the final round will receive a semifinal team plaque for display at their institutions. The second-place team will receive a \$750 cash award (\$250 to each member) and a commemorative team plaque. The winning team will receive a \$1500 cash award (\$500 to each member), and each team member will receive a commemorative plaque. A team trophy will be awarded to the winning institution.

Students are not required to be members of ACCP to participate. Team registration may be submitted online and must be initiated by a current faculty member at the respective institution. Students interested in forming a team should contact their ACCP faculty liaison. If no ACCP Faculty Liaison has been identified, any faculty member from the institution can initiate the registration process. The registering faculty member must confirm the eligibility of all team members and/or alternates online before a team will be permitted to compete.

The deadline to complete your team registration is September 3, 2013.

ACCP National Student Advisory Committee

Initiated as a working group in 2006, the National Student Advisory Group became a standing committee of the College in 2007 whose members are appointed by the ACCP president-elect. The present 11-member committee serves in an advisory capacity to the ACCP Board of Regents and staff, providing feedback and assistance in developing new programs and services for student members. The current committee’s work has focused on two distinct charges:

1. Aside from pursuing campus-based chapters,* determine how ACCP can increase its visibility and organizational interactions with students earlier in their academic experience (i.e., in the P1 and P2 years).
2. Update the Career Pathways section of the Web site at www.accp.com/stunet/pathways.aspx.

Applications for the 2013–2014 National Student Advisory Committee Now Open

Please encourage students at your institution who are interested in learning more about clinical pharmacy to apply for appointment to the 2013–2014 National Student Advisory Committee. This is an excellent opportunity for students to enhance their leadership skills, network with students across the country, and interact with clinical pharmacy leaders. Students appointed to the committee are required to attend the 2013 Annual Meeting and will receive a complimentary student meeting registration. Applicants must submit a current copy of their CV, a 500-word essay detailing their interest in serving on the committee, and a letter of recommendation from an academic dean. Applications are due June 14, 2013. To learn more about the StuNet Advisory Committee or to access the online application portal, please click [here](#).

**This initiative is currently underway. See President’s Column for details.*

ACCP POSTGRADUATE TRAINEE NEWS

The 2012–2013 National Resident Advisory Committee sent a survey to all PRNs to inquire about resident/fellow opportunities within each PRN. The goal is to make these opportunities more visible to postgraduate trainee members of ACCP. Look for this information to be displayed on the Web site in the future.

Forty-one postgraduate trainee members of ACCP are currently participating in the 2012–2013 mentoring program. Mentors are ACCP members who have at least 5 years of professional experience and have volunteered

to participate in the program. Mentor/mentee pairs are encouraged to correspond at least monthly and are provided with timely topics to discuss.

All resident, fellow, and graduate student members of ACCP currently receive a monthly electronic newsletter titled *Experts in Training*. The newsletter primarily highlights the membership benefits of ACCP. If there are topics you'd like to see covered in future editions, submit your ideas to ksims@accp.com.

The College is currently accepting applications for all positions on the 2013–2014 National Resident Advisory Committee. The committee is a working group composed of residents, fellows, and graduate student members of ACCP. Applications for chair, vice chair, and member-at-large positions are due by June 14, 2013.



WASHINGTON UPDATE

ACCP Medicare Coverage Initiative – Direct Patient Care Services of Qualified Clinical Pharmacists as a Covered Medicare Benefit

ACCP considers the PRNs one of its major strengths as an organization. ACCP's PRN members collectively possess a depth of clinical knowledge and expertise that substantially contribute to the College's success.

Just as the PRNs are a vital resource for our strategic mission to develop, advance, and position clinical pharmacists, so too are PRN members essential to our advocacy efforts around the pursuit of achieving recognition of pharmacists' direct patient care services as a covered Medicare benefit.

Our advocacy message focuses on the belief that, to ensure patient-centered, interprofessional health care teams “get the medications right,” qualified clinical pharmacists must be fully integrated into care delivery.

As we define a consistent standard of practice that we believe can help the Medicare program deliver on its “Triple Aim” of better care for patients, better outcomes for populations, and lower costs for the program, there are no better advocates for this effort than the clinical leaders who deliver these services to patients across the country.

For more information on ACCP's advocacy effort, visit our Medicare Coverage Initiative page at www.accp.com/govt/medicare.aspx. To learn how you can get more involved in this effort, visit our Legislative Action Center at capwiz.com/accp/home/.

Outlook for the 113th Congress

The challenging political environment in which we are working to advance our initiative underscores the necessity of PRN members becoming actively engaged as advocates on behalf of the profession.

The need to address our nation's budget deficit dominates the political landscape in Washington. The legislative branch, which once reveled in bloated spending measures weighed down with earmarks and “pork,” is under immense pressure to slash spending. Of note, the formerly dominant [House](#) and [Senate](#) Appropriations Committees, whose chairmen consolidated their own political power through control over annual spending bills, have seen their stature decline as Congress has scaled back its expenditures.¹

The \$85 billion in spending cuts under the terms of the sequestration triggered by the failure of Congress to reach a comprehensive debt-reduction deal by a self-imposed March 1 deadline points to the ongoing stalemate in Washington. Sequestration, after all, was never intended as a solution to government spending but rather was conceived in the hope that the threat of sweeping, across-the-board cuts would encourage both sides to reach a compromise.

Dramatic differences between the [House](#) and [Senate](#) fiscal 2014 budget resolutions further indicate that political Washington remains as gridlocked as the traffic on its notorious Beltway.

However, leaders from both parties have expressed cautious optimism that a solution may be reached.

Early in March, House Speaker John Boehner (R-OH) proposed a deal that would avert a government shut-down when the continuing resolution currently funding government operations expires on March 27.²

Responding to criticism about the president's failure to work effectively with Congress, the White House launched its own “charm offensive,” including several meetings with key congressional Republicans, which initially yielded favorable feedback. Of importance, the Obama administration has increasingly referred to entitlement reform, in addition to revenue increases, as part of its overall platform for deficit reduction.³

Discussion on the Hill (including a series of important [committee hearings](#)) regarding entitlement reform and the need to address the system of Medicare payment, rather than simply propose cuts to the program itself, suggests that Medicare reform legislation will advance with this Congress.

ACCP believes that our Medicare initiative focusing on “getting the medications right” for Medicare beneficiaries is closely aligned with the quality-based,

patient-centered, multiprofessional approach to care that policy-makers already acknowledge as necessary to preserve the long-term integrity of the Medicare program.

Despite the challenging political environment, we are optimistic that with the full engagement of our members, our effort will ultimately be successful.

Advancing Our Medicare Initiative Through Grassroots Action

We believe that our investment in our Washington office and advocacy activities for the past 12 years leaves us well placed to move our initiative forward. But our success ultimately lies in the engagement of ACCP members to help their elected officials understand the importance of getting the medications right as part of patient-centered, team-based models of care delivery.

With more than 13,000 members, not to mention their professional colleagues and patients, ACCP has the potential to exert considerable influence on Capitol Hill. But to realize this potential, we need the active participation of all our members as grassroots advocates.

Identifying Political Champions

In seeking potential champions to advance our initiative in Congress, we need to identify elected officials who not only share our vision of a more patient-centered, team-based, and quality-focused approach to Medicare but also sit on the congressional committees of jurisdiction over the Medicare program itself.

In the House of Representatives, jurisdiction over Medicare is shared between the Energy and Commerce Committee and the Committee on Ways and Means. In the Senate, the Finance Committee oversees Medicare issues. Members who sit on these committees are best placed to introduce legislation on behalf of ACCP and work to ensure its passage into law.

- [Click here](#) to view the members of the Senate Finance Committee
- [Click here](#) to view the members of the House Energy and Commerce Committee
- [Click here](#) to view the members of the House Ways and Means Committee

In addition, legislation would ideally be introduced in a bipartisan manner, meaning a Republican and a Democrat from a committee of jurisdiction would work together to cosponsor a bill on our behalf. Although we acknowledge the challenge of identifying bipartisan cosponsors from the key committees of jurisdiction, we have taken care to ensure our legislative proposal is entirely nonpartisan and focused on issues that members

from both parties can agree on—improving quality and lowering costs in the Medicare program.

To determine whether your elected officials sit on a committee of jurisdiction, visit our [Legislative Action Center](#) and enter your zip code to view your congressional delegation. Check your work zip codes as well as your home address—especially if you practice at several sites. Members of Congress will be interested to learn about innovative, cost-saving care delivery going on in their district, even if you are not a constituent residing in that district.

ACCP's Step-by-Step Guide to Hosting a Visit of Elected Officials to Your Practice

A key element in the internal ACCP discussion leading up to the launch of our legislative initiative was around the need to develop a consistent, standardized process of patient care—recognition that clinical pharmacists' contributions to patient care are often difficult to define and could act as a barrier to achieving recognition and payment for those services.

If this definitional question persists even within the health care community, it is understandable that lawmakers in Congress might struggle to grasp what we are proposing when we call for Medicare Part B coverage of comprehensive medication management services delivered by qualified clinical pharmacists.

Hosting a visit of your elected officials to your practice is perhaps the single most important thing you can do to help lawmakers understand what team-based, patient-centered clinical practice is all about—and to generate their support for recognition and payment for clinical pharmacists' services.

A visit also serves as a means to establish an ongoing constructive dialogue with your congressman or senator, and his or her staff, on issues important to the delivery of team-based, patient-centered care.

A comprehensive guide to inviting a member of Congress to tour your practice site is available on our [Legislative Action Center](#). If you would like to discuss the process of hosting a lawmaker at your practice site, please contact John McGlew at (202) 621-1820 or jmcglew@accp.com.

All ACCP members are urged to consider inviting their elected officials to learn more about their practice through a tour of their practice site.

Advancing Our Medicare Initiative Through the ACCP Political Action Committee (ACCP-PAC)

There is a widely used analogy of advocacy as a three-legged stool—with the three legs consisting of

direct lobbying, grassroots action, and financial support for candidates.

Political contributions are an essential component of our grassroots advocacy toolkit, helping to raise our profile on Capitol Hill and show our support for members of Congress who share our vision for clinical pharmacists in an evolving Medicare program.

A well-funded PAC can be used to show the support within the profession for our legislative initiative and the importance that ACCP members attach to moving it forward in Congress.

ACCP-PAC depends entirely on the support of ACCP members. Although several PACs represent various segments of the pharmacy profession, ACCP has the only PAC dedicated to advancing the practice of clinical pharmacy.

If each ACCP member contributes just \$25, ACCP-PAC will raise \$300,000. All ACCP members should consider donating at least \$25 to ACCP-PAC. [CLICK HERE](#) to support your PAC today!

Contact Us!

For more information on any of ACCP’s advocacy efforts, please contact: John K. McGlew, Associate Director, Government Affairs, American College of Clinical Pharmacy, 1455 Pennsylvania Ave. NW, Suite 400, Washington, DC 20004-1017, (202) 621-1820, jmcglew@accp.com.

References

1. Huffington Post Article. Patrick Leahy Won’t Head Senate Appropriations Committee, Chooses to Remain Senate Judiciary Chair. December 19, 2012. Available [here](#). Accessed March 14, 2013.
2. Washington Post Article. Deal to Avert Government Shutdown Likely, Officials Say. March 3, 2013. Available [here](#). Accessed March 14, 2013.
3. Washington Post Article. Obama Picked Up GOP Senators’ Dinner Tab. March 6, 2013. Available [here](#). Accessed March 14, 2013.

ACCP RESEARCH INSTITUTE UPDATE

We want to share with you an update on the activities and success of the Research Institute. Thank you for supporting the ACCP Research Institute.



Join the ACCP PBRN

The ACCP PBRN is a group of clinical pharmacy members from across the United States delivering clinical pharmacy services at a variety of academic, inpatient, outpatient, and other practice settings. Together, this group forms a nationwide network of pharmacists interested in

answering research questions. To join the ACCP PBRN, please visit our Web site (www.accpri.org) and complete the online registry form. Once you join the registry, you will need to complete a portfolio with **PBRNConnect** so that you can participate in any PBRN project (www.accpri.org/pbrnconnect).

The ACCP PBRN continues to grow since its launch in February 2009. We have more than 800 members to date, including members who belong to existing PRNs and whose data are shown below. We encourage each of you to join!

ACCP PBRN Members	Practice and Research Network
86	Adult Medicine
171	Ambulatory Care
108	Cardiology
20	Central Nervous System
28	Clinical Administration
98	Critical Care
6	Drug Information
64	Education and Training
16	Emergency Medicine
33	Endocrine and Metabolism
32	Geriatrics
20	GI/Liver/Nutrition PRN
14	Health Outcomes
51	Hematology/Oncology
37	Immunology/Transplantation
86	Infectious Diseases
26	Nephrology
27	Pain and Palliative Care
45	Pediatrics
3	Pharmaceutical Industry
17	Pharmacokinetics/Pharmacodynamics/ Pharmacogenomics
21	Women’s Health

How do I join the ACCP PBRN?

The ACCP PBRN has created a one-stop resource for all PBRN-related materials called PBRNConnect. Located at www.accpri.org/pbrnconnect, this resource allows ACCP PBRN members to view, print, and download all research and PBRN-related documents. In addition, PBRNConnect will serve as a repository for all PBRN-related training. Each ACCP PBRN member will need to upload his or her own portfolio documents

within the secure PBRNConnect site to be eligible to participate in ACCP PBRN studies. ACCP PBRN members can access this site using their usual ACCP log-in. Join the more than 200 PBRN members who already have profiles on PBRNConnect.

Calling All Researchers!

Do you have a bright idea for the next ACCP PBRN project? Partner with the ACCP PBRN to complete your project. The ACCP PBRN is committed to supporting the research efforts of its members. We welcome proposals from ACCP PBRN members and other external investigators looking to collaborate with the ACCP PBRN to facilitate practice-based clinical pharmacy research. To learn more about how to collaborate with the ACCP PBRN, please visit www.accpri.org/pbrn/partner.aspx.



ACCP PBRN Announces First Research Publication

The American College of Clinical Pharmacy Practice-Based Research Network (ACCP PBRN) is pleased to announce the publication of its first research paper in the March 2013 issue of *Pharmacotherapy*. The study, titled “Drug Errors and Related Interventions Reported by United States Clinical Pharmacists: The American College of Clinical Pharmacy Practice-Based Research Network Medication Error Detection, Amelioration, and Prevention (MEDAP) Study,” was written by Drs. Grace Kuo (University of California, San Diego), Daniel Touchette (University of Illinois at Chicago), and Jacqueline Marinac (formerly, Director of the ACCP Research Institute) and was supported by the ACCP Frontiers Fund.

The study’s objective was to describe and evaluate drug errors and the corresponding clinical pharmacist interventions. The study involved 62 inpatient and outpatient clinical pharmacists who reported 779 medication errors during a 2-week period, amounting to more than one medication error identified per pharmacist per day. Anti-infective, hematologic, and cardiovascular drugs were most frequently associated with drug errors.

Prescribing errors were the most common type, resulting in 53% of all medication errors identified. Most (89%) pharmacist recommendations in managing medication errors were accepted by prescribers. Although most of the drug errors did not result in harm, early detection of the error by a clinical pharmacist may have prevented unnecessary morbidity.

This study highlights the potential for clinical pharmacists and the PBRN to identify opportunities

for documenting and improving the impact of clinical pharmacists on patient care. The full study report is available at www.accp.com/docs/positions/research/MEDAP_Drug_Errors.pdf. Two follow-up reports, one describing the feasibility of conducting research within the PBRN and the other evaluating the economic impact of the medication errors, are nearing completion.

The ACCP PBRN would like to thank the 62 clinical pharmacists who participated in the MEDAP Study. A list of the participants can be found at www.accpri.org/pbrn/researchProjects.aspx. If you are interested in participating in future studies but are not currently a PBRN member, contact the PBRN at pbrn@accp.com. For more information about the PBRN, please visit its Web site at www.accpri.org/pbrn.

Update on the ACCP Activities Characterizing Clinical Pharmacists (ACCP²) Study

The ACCP² Study is a mixed methods study with the goal of developing an infrastructure within the ACCP Practice-Based Research Network (PBRN) to conduct research evaluating the impact of clinical pharmacist activities. This study’s objective is to describe clinical pharmacist cognitive processes, including gathering information, setting the goals of therapy, developing a treatment plan, and communicating with patients and practitioners in the delivery of patient care in general inpatient and outpatient settings.

The first part of this mixed methods study used qualitative methods to better identify specific activities performed by clinical pharmacists in their practices. In total, 22 clinical pharmacists were interviewed by telephone. Telephone interviews were used to develop the initial focus group facilitator’s guide. Six focus groups were conducted from October 2012 through February 2013. Transcripts collected from the telephone interviews and focus groups were used to identify common themes in patient care by clinical pharmacists. The results of the qualitative study are currently being analyzed and prepared for submission to a major health care conference and for publication.

The interviews and focus group transcripts are also being used to develop a point-of-care documentation tool to be used in a subsequent quantitative research study to capture the activities of a single clinical pharmacist interaction with a patient. From this study, the PBRN will be better able to describe and understand factors that influence patient care delivery by a clinical pharmacist. The quantitative study will be conducted using the PBRN and will begin recruitment after IRB

approval is obtained. Inpatient and outpatient clinical pharmacist PBRN members will be contacted by e-mail in the near future to request their participation. If you are not currently a PBRN member but are interested in joining the PBRN and participating in this study, contact the PBRN at pbrn@accp.com.

2013 Frontiers Fund Committee:

Ron Evens
Susan Fagan (Chair)
Stuart Haines
Ralph Raasch

Frontiers Fund: Celebrating Success

The Frontiers Fund helped establish the first national clinical pharmacy practice-based research network (PBRN). We recognize that the PBRN's success is made possible in large part by the contributions of several hundred ACCP members and organizations, as well as many PRNs. However, further success cannot be achieved without additional support. Your tax-deductible donation will develop researchers, build the ACCP PBRN, and generate evidence to further document the value of clinical pharmacy services and advance pharmacy research.

The 2013 Frontiers Fund goals are to receive \$100,000 in donations and to increase the percentage of members who donate from 4% to 6%. More information about the Frontiers Fund, including a complete list of donors since 1998, is available at www.accpri.org. Please consider donating to help the Frontiers Fund in 2013 and join the others who have contributed to its success. You can also make online donations at www.accpri.org.

MAKE PLANS TO ATTEND THE 2013 ACCP ANNUAL MEETING

October 13–16, 2013, in Albuquerque, New Mexico

Join your colleagues and mentors at the 2013 ACCP Annual Meeting, October 13–16, 2013, in Albuquerque, New Mexico. The ACCP Annual Meeting offers stellar educational programming on the most topical issues, interactive professional development sessions with renowned presenters, and several networking opportunities that will provide you with access to the leaders and groundbreakers of clinical pharmacy.

Attendees will enjoy state-of-the-art meeting facilities at the newly renovated Albuquerque Convention

Center, which is set against a backdrop of the modern downtown skyline and the ancient Sandia Mountains. ACCP has selected the prestigious Hyatt Regency Albuquerque as its headquarters hotel and the trendy DoubleTree by Hilton Albuquerque as a second housing option, both located just steps from the Albuquerque Convention Center. As an annual meeting attendee, you will experience the authentic Southwest in Albuquerque, which offers a wide array of cultural dining options, world-class visual and performing arts, and a vast collection of shops, boutiques, and galleries, all within minutes of the convention center.

The educational program developed for the ACCP Annual Meeting provides high-quality sessions covering novel topics and issues that are challenging and applicable to your practice. The 2013 Annual Meeting will offer the three curricular tracks focusing on emerging clinical and professional issues, PRN-developed focus sessions, and Academy programming developed for each of the four ACCP Academy certificate programs. The meeting's schedule of events will include the highly anticipated scientific paper platform presentations, the poster presentations, and the Town Hall Meeting. Attendees also won't want to miss the increasingly popular semifinal and final rounds of the fourth annual ACCP Clinical Pharmacy Challenge, which draws talented student teams from the nation's top pharmacy schools. Registration for the 2013 Annual Meeting will open in June. Watch the ACCP Web site for more details.

PRN MEMBERSHIP TOTALS

Ambulatory Care	1,495
Adult Medicine	981
Clinical Administration	382
Cardiology	1,038
Central Nervous System	187
Critical Care	1,787
Drug Information	290
Education and Training	428
Emergency Medicine	476
Endocrine and Metabolism	245
Geriatrics	321
GI/Liver/Nutrition	163
Hematology/Oncology	616
Immunology/Transplantation	387
Pharmaceutical Industry	240
Infectious Diseases	1,654
Nephrology	203
Health Outcomes	146
Pain and Palliative Care	308
Pediatrics	674
Pharmacokinetics/Pharmacodynamics/Pharmacogenomics	227
Women's Health	172
TOTAL	12,420

(As of March 1, 2013)

PRN CONTACT INFORMATION

For more information about a specific PRN, please contact the PRN's chair identified below.

Adult Medicine	Jessica A. Starr, Pharm.D., BCPS
Ambulatory Care	Daniel S. Longyhore, Pharm.D., BCACP
Cardiology	Paul P. Dobesh, Pharm.D., FCCP, BCPS
Central Nervous System	Jack J. Chen, Pharm.D., FCCP, BCPS
Clinical Administration	Harminder Sikand, Pharm.D.
Critical Care	Stacy A. Voils, Pharm.D., BCPS
Drug Information	Jennifer Phillips, Pharm.D., BCPS
Education and Training	Samantha A. Karr, Pharm.D., BCPS, BCACP
Emergency Medicine	Nicole M. Acquisto, Pharm.D., BCPS
Endocrine and Metabolism	Jennifer N. Clements, Pharm.D., BCPS, CDE
Geriatrics	Gregory J. Hughes, Pharm.D.
GI/Liver/Nutrition	Rima A. Mohammad, Pharm.D., BCPS
Health Outcomes	James D. Nash, Pharm.D., BCPS
Hematology/Oncology	Rebecca J. Fahrenbruch, Pharm.D., BCOP
Immunology/Transplantation	Angela Q. Maldonado, Pharm.D., BCPS
Infectious Diseases	Jessica Cottreau, Pharm.D., BCPS
Nephrology	Mariann D. Churchwell, Pharm.D., BCPS
Pain and Palliative Care	Mary Lynn McPherson, Pharm.D., BCPS
Pediatrics	Hanna Phan, Pharm.D., BCPS
Pharmaceutical Industry	Rachel L. Couchenour, Pharm.D., MBA
Pharmacokinetics/Pharmacodynamics/Pharmacogenomics	Varsha Bhatt-Mehta, Pharm.D., FCCP
Women's Health	Sarah McBane, Pharm.D.